BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Crespo J. Gene expression of tumor necrosis factor [alpha ] and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001;34:1158-63. [DOI: 10.1053/jhep.2001.29628] [Cited by in Crossref: 445] [Cited by in F6Publishing: 433] [Article Influence: 21.2] [Reference Citation Analysis]
Number Citing Articles
1 Lewis JR, Mohanty SR. Nonalcoholic Fatty Liver Disease: A Review and Update. Dig Dis Sci 2010;55:560-78. [DOI: 10.1007/s10620-009-1081-0] [Cited by in Crossref: 212] [Cited by in F6Publishing: 211] [Article Influence: 17.7] [Reference Citation Analysis]
2 Yoshio S, Kanto T. Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease. Immunol Med 2021;44:175-86. [PMID: 33444517 DOI: 10.1080/25785826.2020.1868664] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Aparicio-Vergara M, Hommelberg PP, Schreurs M, Gruben N, Stienstra R, Shiri-Sverdlov R, Kloosterhuis NJ, de Bruin A, van de Sluis B, Koonen DP, Hofker MH. Tumor necrosis factor receptor 1 gain-of-function mutation aggravates nonalcoholic fatty liver disease but does not cause insulin resistance in a murine model. Hepatology. 2013;57:566-576. [PMID: 22941955 DOI: 10.1002/hep.26046] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
4 Yan F, Fu Q. PLCε1: A potential target of RNA interference therapy for gastric cancer. Biochemical and Biophysical Research Communications 2014;448:409-13. [DOI: 10.1016/j.bbrc.2014.04.119] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
5 Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016;65:1038-48. [DOI: 10.1016/j.metabol.2015.12.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Chenxu G, Minxuan X, Yuting Q, Tingting G, Jing F, Jinxiao L, Sujun W, Yongjie M, Deshuai L, Qiang L, Linfeng H, Xuyuan N, Mingxing W, Ping H, Jun T. Loss of RIP3 initiates annihilation of high-fat diet initialized nonalcoholic hepatosteatosis: A mechanism involving Toll-like receptor 4 and oxidative stress. Free Radical Biology and Medicine 2019;134:23-41. [DOI: 10.1016/j.freeradbiomed.2018.12.034] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
7 Hirsova P, Gores GJ. Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis. Cell Mol Gastroenterol Hepatol 2015;1:17-27. [PMID: 25729762 DOI: 10.1016/j.jcmgh.2014.11.005] [Cited by in Crossref: 98] [Cited by in F6Publishing: 100] [Article Influence: 14.0] [Reference Citation Analysis]
8 Tsuruta Y, Nagao K, Shirouchi B, Nomura S, Tsuge K, Koganemaru K, Yanagita T. Effects of Lotus Root (the Edible Rhizome of Nelumbo nucifera ) on the Deveolopment of Non-Alcoholic Fatty Liver Disease in Obese Diabetic db/db Mice. Bioscience, Biotechnology, and Biochemistry 2014;76:462-6. [DOI: 10.1271/bbb.110745] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
9 Ramalho RM, Cortez-Pinto H, Castro RE, Solá S, Costa A, Moura MC, Camilo ME, Rodrigues CM. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2006;18:21-29. [PMID: 16357615 DOI: 10.1097/00042737-200601000-00005] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 3.8] [Reference Citation Analysis]
10 Persico M, Iolascon A. Steatosis as a co-factor in chronic liver diseases. World J Gastroenterol 2010; 16(10): 1171-1176 [PMID: 20222159 DOI: 10.3748/wjg.v16.i10.1171] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
11 Kim MS, Kim IY, Sung HR, Nam M, Kim YJ, Kyung DS, Seong JK, Hwang GS. Metabolic dysfunction following weight regain compared to initial weight gain in a high-fat diet-induced obese mouse model. J Nutr Biochem 2019;69:44-52. [PMID: 31048208 DOI: 10.1016/j.jnutbio.2019.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
12 Su YB, Li TH, Huang CC, Tsai HC, Huang SF, Hsieh YC, Yang YY, Huang YH, Hou MC, Lin HC. Chronic calcitriol supplementation improves the inflammatory profiles of circulating monocytes and the associated intestinal/adipose tissue alteration in a diet-induced steatohepatitis rat model. PLoS One 2018;13:e0194867. [PMID: 29684027 DOI: 10.1371/journal.pone.0194867] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
13 Hwang YJ, Wi HR, Kim HR, Park KW, Hwang KA. Pinus densiflora Sieb. et Zucc. alleviates lipogenesis and oxidative stress during oleic acid-induced steatosis in HepG2 cells. Nutrients 2014;6:2956-72. [PMID: 25057104 DOI: 10.3390/nu6072956] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
14 Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin Liver Dis 2009;13:565-80. [PMID: 19818305 DOI: 10.1016/j.cld.2009.07.003] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 5.9] [Reference Citation Analysis]
15 Sardana O, Goyal R, Bedi O. Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD. Inflammopharmacology 2021;29:1061-74. [PMID: 34185201 DOI: 10.1007/s10787-021-00837-4] [Reference Citation Analysis]
16 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
17 Eiszrich Á, Fehér J. Fatty liver in childhood. Orvosi Hetilap 2007;148:2461-8. [DOI: 10.1556/oh.2007.28270] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. J Gastroenterol. 2008;43:811-822. [PMID: 19012034 DOI: 10.1007/s00535-008-2213-6] [Cited by in Crossref: 103] [Cited by in F6Publishing: 96] [Article Influence: 7.4] [Reference Citation Analysis]
19 Najjar SM, Ledford KJ, Abdallah SL, Paus A, Russo L, Kaw MK, Ramakrishnan SK, Muturi HT, Raphael CK, Lester SG, Heinrich G, Pierre SV, Benndorf R, Kleff V, Jaffa AA, Lévy E, Vazquez G, Goldberg IJ, Beauchemin N, Scalia R, Ergün S. Ceacam1 deletion causes vascular alterations in large vessels. Am J Physiol Endocrinol Metab 2013;305:E519-29. [PMID: 23800882 DOI: 10.1152/ajpendo.00266.2013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
20 Marinho PC, Vieira AB, Pereira PG, Rabelo K, Ciambarella BT, Nascimento ALR, Cortez E, Moura AS, Guimarães FV, Martins MA, Barquero G, Ferreira RN, de Carvalho JJ. Capybara Oil Improves Hepatic Mitochondrial Dysfunction, Steatosis, and Inflammation in a Murine Model of Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2018;2018:4956079. [PMID: 29853957 DOI: 10.1155/2018/4956079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Zhu QX, Deng CS. Detection of TNF-α, TGF-β1 and hs-CRP and its clinical significance in non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2008; 16(34): 3910-3912 [DOI: 10.11569/wcjd.v16.i34.3910] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Mohamed RH, Tarek M, Hamam GG, Ezzat SF. Zoledronic acid prevents the hepatic changes associated with high fat diet in rats; the potential role of mevalonic acid pathway in nonalcoholic steatohepatitis. European Journal of Pharmacology 2019;858:172469. [DOI: 10.1016/j.ejphar.2019.172469] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
23 Hwang D, Park HR, Lee SJ, Kim HW, Kim JH, Shin KS. Oral administration of palatinose vs sucrose improves hyperglycemia in normal C57BL/6J mice. Nutr Res 2018;59:44-52. [PMID: 30442232 DOI: 10.1016/j.nutres.2018.06.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
24 García-Ruiz I, Rodríguez-Juan C, Díaz-Sanjuan T, del Hoyo P, Colina F, Muñoz-Yagüe T, Solís-Herruzo JA. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology 2006;44:581-91. [PMID: 16941682 DOI: 10.1002/hep.21313] [Cited by in Crossref: 134] [Cited by in F6Publishing: 131] [Article Influence: 8.4] [Reference Citation Analysis]
25 Ditzel EJ, Nguyen T, Parker P, Camenisch TD. Effects of Arsenite Exposure during Fetal Development on Energy Metabolism and Susceptibility to Diet-Induced Fatty Liver Disease in Male Mice. Environ Health Perspect 2016;124:201-9. [PMID: 26151952 DOI: 10.1289/ehp.1409501] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 7.1] [Reference Citation Analysis]
26 Li X, Jiao Y, Xing Y, Gao P. Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis. Biomed Res Int. 2019;2019:5308308. [PMID: 31080822 DOI: 10.1155/2019/5308308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
27 Yoshimura E, Kumahara H, Tobina T, Matono S, Kiyonaga A, Kimura M, Tsukikawa H, Kono S, Etou T, Irie S. Relationships between fat deposition in the liver and skeletal muscle and insulin sensitivity in Japanese individuals: a pilot study. Diabetes Metab Syndr Obes. 2011;4:35-43. [PMID: 21448320 DOI: 10.2147/dmso.s16175] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
28 Paquot N, Delwaide J. Fatty liver in the intensive care unit: . Current Opinion in Clinical Nutrition and Metabolic Care 2005;8:183-7. [DOI: 10.1097/00075197-200503000-00013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
29 Sahai A, Malladi P, Melin-aldana H, Green RM, Whitington PF. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. American Journal of Physiology-Gastrointestinal and Liver Physiology 2004;287:G264-73. [DOI: 10.1152/ajpgi.00002.2004] [Cited by in Crossref: 137] [Cited by in F6Publishing: 133] [Article Influence: 7.6] [Reference Citation Analysis]
30 Miele L, Forgione A, Gasbarrini G, Grieco A. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res. 2007;149:114-125. [PMID: 17320797 DOI: 10.1016/j.trsl.2006.11.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
31 Sundaram SS, Whitington PF, Green RM. Steatohepatitis develops rapidly in transgenic mice overexpressing Abcb11 and fed a methionine-choline-deficient diet. American Journal of Physiology-Gastrointestinal and Liver Physiology 2005;288:G1321-7. [DOI: 10.1152/ajpgi.00455.2004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
32 Reis SR, Feres NH, Ignacio-Souza LM, Veloso RV, Arantes VC, Kawashita NH, Colodel EM, Botosso BL, Reis MA, Latorraca MQ. Nutritional recovery with a soybean diet after weaning reduces lipogenesis but induces inflammation in the liver in adult rats exposed to protein restriction during intrauterine life and lactation. Mediators Inflamm 2015;2015:781703. [PMID: 25892856 DOI: 10.1155/2015/781703] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
33 Niederreiter L, Tilg H. Cytokines and fatty liver diseases. Liver Research 2018;2:14-20. [DOI: 10.1016/j.livres.2018.03.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 7.8] [Reference Citation Analysis]
34 Chen J, Liu J, Wang Y, Hu X, Zhou F, Hu Y, Yuan Y, Xu Y. Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARα/AdipoR2, in vivo and in vitro. Biomed Pharmacother 2017;91:621-31. [PMID: 28486193 DOI: 10.1016/j.biopha.2017.04.125] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
35 Lee YM, Sutedja DS, Wai CT, Dan YY, Aung MO, Zhou L, Cheng CL, Wee A, Lim SG. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008;2:196-201. [PMID: 19669304 DOI: 10.1007/s12072-008-9058-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 3.5] [Reference Citation Analysis]
36 Canivet CM, Bonnafous S, Rousseau D, Leclere PS, Lacas-Gervais S, Patouraux S, Sans A, Luci C, Bailly-Maitre B, Iannelli A, Tran A, Anty R, Gual P. Hepatic FNDC5 is a potential local protective factor against Non-Alcoholic Fatty Liver. Biochim Biophys Acta Mol Basis Dis 2020;1866:165705. [PMID: 32001301 DOI: 10.1016/j.bbadis.2020.165705] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
37 Gong Z, Tas E, Yakar S, Muzumdar R. Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging. Mol Cell Endocrinol. 2017;455:115-130. [PMID: 28017785 DOI: 10.1016/j.mce.2016.12.022] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
38 Wang J, Ortiz C, Fontenot L, Mukhopadhyay R, Xie Y, Law IKM, Shih DQ, Mattai SA, Li Z, Koon HW. Elafin inhibits obesity, hyperglycemia, and liver steatosis in high-fat diet-treated male mice. Sci Rep 2020;10:12785. [PMID: 32733043 DOI: 10.1038/s41598-020-69634-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Day CP, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol. 2002;17 Suppl 3:S377-S384. [PMID: 12472967 DOI: 10.1046/j.1440-1746.17.s3.31.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 109] [Article Influence: 7.4] [Reference Citation Analysis]
40 Coulon S, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F, De Munter S, Prawitt J, Caron S, Staels B, Van Vlierberghe H, Van Gaal L, Geerts A. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine 2012;59:442-9. [DOI: 10.1016/j.cyto.2012.05.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 6.4] [Reference Citation Analysis]
41 dela Peña A, Leclercq I, Field J, George J, Jones B, Farrell G. NF-κB Activation, Rather Than TNF, Mediates Hepatic Inflammation in a Murine Dietary Model of Steatohepatitis. Gastroenterology 2005;129:1663-74. [DOI: 10.1053/j.gastro.2005.09.004] [Cited by in Crossref: 200] [Cited by in F6Publishing: 202] [Article Influence: 11.8] [Reference Citation Analysis]
42 Shams ME, Al-Gayyar MM, Barakat EA. Type 2 Diabetes Mellitus-Induced Hyperglycemia in Patients with NAFLD and Normal LFTs: Relationship to Lipid Profile, Oxidative Stress and Pro-Inflammatory Cytokines. Sci Pharm. 2011;79:623-634. [PMID: 21886908 DOI: 10.3797/scipharm.1104-21] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
43 Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002;16:663-678. [PMID: 12406438 DOI: 10.1053/bega.2002.0333] [Cited by in Crossref: 283] [Cited by in F6Publishing: 273] [Article Influence: 14.9] [Reference Citation Analysis]
44 Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010;103:71-83. [PMID: 19914930 DOI: 10.1093/qjmed/hcp158] [Cited by in Crossref: 392] [Cited by in F6Publishing: 366] [Article Influence: 30.2] [Reference Citation Analysis]
45 Sharma M, Mitnala S, Vishnubhotla RK, Mukherjee R, Reddy DN, Rao PN. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. J Clin Exp Hepatol. 2015;5:147-158. [PMID: 26155043 DOI: 10.1016/j.jceh.2015.02.002] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 10.0] [Reference Citation Analysis]
46 Afonso MB, Rodrigues PM, Carvalho T, Caridade M, Borralho P, Cortez-Pinto H, Castro RE, Rodrigues CM. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis. Clin Sci (Lond). 2015;129:721-739. [PMID: 26201023 DOI: 10.1042/cs20140732] [Cited by in Crossref: 98] [Cited by in F6Publishing: 58] [Article Influence: 14.0] [Reference Citation Analysis]
47 Tran A, Gual P. Non-alcoholic steatohepatitis in morbidly obese patients. Clin Res Hepatol Gastroenterol. 2013;37:17-29. [PMID: 23347840 DOI: 10.1016/j.clinre.2012.07.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
48 Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6:1-28. [PMID: 16406828 DOI: 10.1016/j.mito.2005.10.004] [Cited by in Crossref: 434] [Cited by in F6Publishing: 426] [Article Influence: 27.1] [Reference Citation Analysis]
49 Manco M, Putignani L, Bottazzo GF. Gut Microbiota, Lipopolysaccharides, and Innate Immunity in the Pathogenesis of Obesity and Cardiovascular Risk. Endocrine Reviews 2010;31:817-44. [DOI: 10.1210/er.2009-0030] [Cited by in Crossref: 268] [Cited by in F6Publishing: 262] [Article Influence: 22.3] [Reference Citation Analysis]
50 Komolkriengkrai M, Nopparat J, Vongvatcharanon U, Anupunpisit V, Khimmaktong W. Effect of glabridin on collagen deposition in liver and amelioration of hepatocyte destruction in diabetes rats. Exp Ther Med 2019;18:1164-74. [PMID: 31316610 DOI: 10.3892/etm.2019.7664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Baumgardner JN, Shankar K, Hennings L, Badger TM, Ronis MJ. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am J Physiol Gastrointest Liver Physiol. 2008;294:G27-G38. [PMID: 17947452 DOI: 10.1152/ajpgi.00296.2007] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 6.0] [Reference Citation Analysis]
52 Shoji H, Yoshio S, Mano Y, Kumagai E, Sugiyama M, Korenaga M, Arai T, Itokawa N, Atsukawa M, Aikata H, Hyogo H, Chayama K, Ohashi T, Ito K, Yoneda M, Nozaki Y, Kawaguchi T, Torimura T, Abe M, Hiasa Y, Fukai M, Kamiyama T, Taketomi A, Mizokami M, Kanto T. Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep 2016;6:28814. [PMID: 27363523 DOI: 10.1038/srep28814] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
53 Malaguarnera L, Di Rosa M, Zambito AM, dell’Ombra N, Nicoletti F, Malaguarnera M. Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. Gut. 2006;55:1313-1320. [PMID: 16825325 DOI: 10.1136/gut.2005.075697] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 4.2] [Reference Citation Analysis]
54 Sugihara T, Koda M, Kishina M, Kato J, Tokunaga S, Matono T, Ueki M, Murawaki Y. Fatty liver Shionogi-ob/ob mouse: A new candidate for a non-alcoholic steatohepatitis model. Hepatol Res. 2013;43:547-556. [PMID: 23057725 DOI: 10.1111/j.1872-034x.2012.01101.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
55 Jorge ASB, Andrade JMO, Paraíso AF, Jorge GCB, Silveira CM, de Souza LR, Santos EP, Guimaraes ALS, Santos SHS, De-paula AMB. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity. Obesity Research & Clinical Practice 2018;12:1-8. [DOI: 10.1016/j.orcp.2016.03.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
56 Yadav SK, Adhikary B, Bandyopadhyay SK, Chattopadhyay S. Inhibition of TNF-α, and NF-κB and JNK pathways accounts for the prophylactic action of the natural phenolic, allylpyrocatechol against indomethacin gastropathy. Biochim Biophys Acta. 2013;1830:3776-3786. [PMID: 23523691 DOI: 10.1016/j.bbagen.2013.03.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
57 Moriya T, Kitamori K, Naito H, Yanagiba Y, Ito Y, Yamagishi N, Tamada H, Jia X, Tsuchikura S, Ikeda K, Yamori Y, Nakajima T. Simultaneous changes in high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis and those underlying molecular mechanisms in novel SHRSP5/Dmcr rat. Environ Health Prev Med 2012;17:444-56. [PMID: 22407906 DOI: 10.1007/s12199-012-0273-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
58 van Herpen NA, Schrauwen-Hinderling VB. Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol Behav. 2008;94:231-241. [PMID: 18222498 DOI: 10.1016/j.physbeh.2007.11.049] [Cited by in Crossref: 304] [Cited by in F6Publishing: 287] [Article Influence: 20.3] [Reference Citation Analysis]
59 Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark Ed) 2021;26:206-37. [PMID: 33049668 DOI: 10.2741/4892] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
60 Capeau J. Insulin resistance and steatosis in humans. Diabetes & Metabolism 2008;34:649-57. [DOI: 10.1016/s1262-3636(08)74600-7] [Cited by in Crossref: 76] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
61 Rajesh Y, Sarkar D. Association of Adipose Tissue and Adipokines with Development of Obesity-Induced Liver Cancer. Int J Mol Sci 2021;22:2163. [PMID: 33671547 DOI: 10.3390/ijms22042163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Reference Citation Analysis]
63 Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol 2014;5:177. [PMID: 24795720 DOI: 10.3389/fimmu.2014.00177] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 9.8] [Reference Citation Analysis]
64 Malnick SD, Beergabel M, Knobler H. Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. QJM. 2003;96:699-709. [PMID: 14500857 DOI: 10.1093/qjmed/hcg120] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
65 Du J, Ma YY, Yu CH, Li YM. Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol 2014; 20(2): 569-577 [PMID: 24574727 DOI: 10.3748/wjg.v20.i2.569] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
66 Chakraborty S, Yadav SK, Saha B, Tyagi M, Singh Rathee J, Chattopadhyay S. A bis-resorcinol resveratrol congener prevents indomethacin-induced gastric ulceration by inhibiting TNF-α as well as NF-κB and JNK pathways. Free Radical Research 2019;53:596-610. [DOI: 10.1080/10715762.2019.1572887] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
67 Lemoine M, Barbu V, Girard PM, Kim M, Bastard JP, Wendum D, Paye F, Housset C, Capeau J, Serfaty L. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS. 2006;20:387-395. [PMID: 16439872 DOI: 10.1097/01.aids.0000206503.01536.11] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 4.9] [Reference Citation Analysis]
68 Rada P, González-Rodríguez Á, García-Monzón C, Valverde ÁM. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis 2020;11:802. [PMID: 32978374 DOI: 10.1038/s41419-020-03003-w] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
69 Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:6184-6223. [PMID: 24733068 DOI: 10.3390/ijms15046184] [Cited by in Crossref: 862] [Cited by in F6Publishing: 787] [Article Influence: 107.8] [Reference Citation Analysis]
70 Chu H, Williams B, Schnabl B. Gut microbiota, fatty liver disease, and hepatocellular carcinoma. Liver Res. 2018;2:43-51. [PMID: 30416839 DOI: 10.1016/j.livres.2017.11.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
71 Kawaratani H, Tsujimoto T, Douhara A, Takaya H, Moriya K, Namisaki T, Noguchi R, Yoshiji H, Fujimoto M, Fukui H. The effect of inflammatory cytokines in alcoholic liver disease. Mediators Inflamm. 2013;2013:495156. [PMID: 24385684 DOI: 10.1155/2013/495156] [Cited by in Crossref: 111] [Cited by in F6Publishing: 96] [Article Influence: 12.3] [Reference Citation Analysis]
72 Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56:952-964. [PMID: 22173168 DOI: 10.1016/j.jhep.2011.08.025] [Cited by in Crossref: 452] [Cited by in F6Publishing: 440] [Article Influence: 41.1] [Reference Citation Analysis]
73 Zhou J, Long Y, Ding N, Su Y. Association between bedtime at night and nonalcoholic fatty liver disease diagnosed by liver ultrasound transient elastography. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109195] [Reference Citation Analysis]
74 Jiang N, Xin W, Wang T, Zhang L, Fan H, Du Y, Li C, Fu F. Protective effect of aescin from the seeds of Aesculus hippocastanum on liver injury induced by endotoxin in mice. Phytomedicine 2011;18:1276-84. [DOI: 10.1016/j.phymed.2011.06.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
75 García-Compeán D, Jáquez-Quintana JO, González-González JA, Lavalle-González FJ, Villarreal-Pérez JZ, Maldonado-Garza HJ. [Diabetes in liver cirrhosis]. Gastroenterol Hepatol 2013;36:473-82. [PMID: 23628170 DOI: 10.1016/j.gastrohep.2013.01.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
76 Ehrampoush E, Ghaemi A, Osati S, Maleki M, Raeisi Shahraki H, Honarvar B, Bahmanyar M, Homayounfar R. The Association Between Serum Vitamin D Level and Nonalcoholic Fatty Liver Disease. Hepat Mon 2019;19. [DOI: 10.5812/hepatmon.92992] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Louthan MV, Barve S, Mcclain CJ, Joshi-barve S. Decreased Serum Adiponectin: An Early Event in Pediatric Nonalcoholic Fatty Liver Disease. The Journal of Pediatrics 2005;147:835-8. [DOI: 10.1016/j.jpeds.2005.07.030] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 4.1] [Reference Citation Analysis]
78 Bourrie BCT, Ju T, Fouhse JM, Forgie AJ, Sergi C, Cotter PD, Willing BP. Kefir microbial composition is a deciding factor in the physiological impact of kefir in a mouse model of obesity. Br J Nutr 2021;125:129-38. [PMID: 32684173 DOI: 10.1017/S0007114520002743] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
79 Di Rosa M, Malaguarnera L. Genetic variants in candidate genes influencing NAFLD progression. J Mol Med (Berl). 2012;90:105-118. [PMID: 21894552 DOI: 10.1007/s00109-011-0803-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
80 Koek G, Liedorp P, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clinica Chimica Acta 2011;412:1297-305. [DOI: 10.1016/j.cca.2011.04.013] [Cited by in Crossref: 202] [Cited by in F6Publishing: 195] [Article Influence: 18.4] [Reference Citation Analysis]
81 Utzschneider KM, Kahn SE. The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease. The Journal of Clinical Endocrinology & Metabolism 2006;91:4753-61. [DOI: 10.1210/jc.2006-0587] [Cited by in Crossref: 476] [Cited by in F6Publishing: 451] [Article Influence: 29.8] [Reference Citation Analysis]
82 Shimizu M, Kubota M, Tanaka T, Moriwaki H. Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. Int J Mol Sci. 2012;13:579-595. [PMID: 22312273 DOI: 10.3390/ijms13010579] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
83 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3478/wjg.v20.i7.1712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, Smirčić Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(48): 18070-18091 [PMID: 25561778 DOI: 10.3748/wjg.v20.i48.18070] [Cited by in CrossRef: 176] [Cited by in F6Publishing: 157] [Article Influence: 22.0] [Reference Citation Analysis]
85 Moreno Sánchez D. [Pathogenesis of primary nonalcoholic fatty liver disease]. Med Clin (Barc) 2005;124:668-77. [PMID: 15882516 DOI: 10.1157/13074744] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
86 Yoshimura E, Kumahara H, Tobina T, Matsuda T, Ayabe M, Kiyonaga A, Anzai K, Higaki Y, Tanaka H. Lifestyle intervention involving calorie restriction with or without aerobic exercise training improves liver fat in adults with visceral adiposity. J Obes. 2014;2014:197216. [PMID: 24864199 DOI: 10.1155/2014/197216] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
87 Duvnjak M, Lerotić I, Baršić N, Tomašić V, Jukić LV, Velagić V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 2007; 13(34): 4539-4550 [PMID: 17729403 DOI: 10.3748/wjg.v13.i34.4539] [Cited by in CrossRef: 157] [Cited by in F6Publishing: 142] [Article Influence: 10.5] [Reference Citation Analysis]
88 Adenote A, Dumic I, Madrid C, Barusya C, Nordstrom CW, Rueda Prada L. NAFLD and Infection, a Nuanced Relationship. Can J Gastroenterol Hepatol 2021;2021:5556354. [PMID: 33977096 DOI: 10.1155/2021/5556354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Hodges JK, Sasaki GY, Bruno RS. Anti-inflammatory activities of green tea catechins along the gut-liver axis in nonalcoholic fatty liver disease: lessons learned from preclinical and human studies. J Nutr Biochem 2020;85:108478. [PMID: 32801031 DOI: 10.1016/j.jnutbio.2020.108478] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
90 Kurita S, Takamura T, Ota T, Matsuzawa-nagata N, Kita Y, Uno M, Nabemoto S, Ishikura K, Misu H, Ando H, Zen Y, Nakanuma Y, Kaneko S. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects. European Journal of Pharmacology 2008;588:316-24. [DOI: 10.1016/j.ejphar.2008.04.028] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
91 Parola M, Marra F. Adipokines and Redox Signaling: Impact on Fatty Liver Disease. Antioxidants & Redox Signaling 2011;15:461-83. [DOI: 10.1089/ars.2010.3848] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
92 Sethi JK, Hotamisligil GS. Metabolic Messengers: tumour necrosis factor. Nat Metab 2021;3:1302-12. [PMID: 34650277 DOI: 10.1038/s42255-021-00470-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Gui SY, Wei W, Wang H, Wu L, Sun WY, Wu CY. Protective effect of fufanghuangqiduogan against acute liver injury in mice. World J Gastroenterol 2005; 11(19): 2984-2989 [PMID: 15902742 DOI: 10.3748/wjg.v11.i19.2984] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
94 Marí M, de Gregorio E, de Dios C, Roca-Agujetas V, Cucarull B, Tutusaus A, Morales A, Colell A. Mitochondrial Glutathione: Recent Insights and Role in Disease. Antioxidants (Basel) 2020;9:E909. [PMID: 32987701 DOI: 10.3390/antiox9100909] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
95 Hu M, Phan F, Bourron O, Ferré P, Foufelle F. Steatosis and NASH in type 2 diabetes. Biochimie 2017;143:37-41. [DOI: 10.1016/j.biochi.2017.10.019] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
96 Fitzpatrick E, Dew TK, Quaglia A, Sherwood RA, Mitry RR, Dhawan A. Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease. Pediatr Obes. 2012;7:471-479. [PMID: 22962039 DOI: 10.1111/j.2047-6310.2012.00082.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
97 Kim YM, Kim TH, Kim YW, Yang YM, Ryu DH, Hwang SJ, Lee JR, Kim SC, Kim SG. Inhibition of liver X receptor-α-dependent hepatic steatosis by isoliquiritigenin, a licorice antioxidant flavonoid, as mediated by JNK1 inhibition. Free Radic Biol Med 2010;49:1722-34. [PMID: 20840863 DOI: 10.1016/j.freeradbiomed.2010.09.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
98 George J, Liddle C. Nonalcoholic Fatty Liver Disease: Pathogenesis and Potential for Nuclear Receptors as Therapeutic Targets. Mol Pharmaceutics 2008;5:49-59. [DOI: 10.1021/mp700110z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 3.7] [Reference Citation Analysis]
99 Caballero F, Fernández A, De Lacy AM, Fernández-Checa JC, Caballería J, García-Ruiz C. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol. 2009;50:789-796. [PMID: 19231010 DOI: 10.1016/j.jhep.2008.12.016] [Cited by in Crossref: 222] [Cited by in F6Publishing: 207] [Article Influence: 17.1] [Reference Citation Analysis]
100 Conrotto D, Bugianesi E, Chiusa L, Carrozzo M. Non-alcoholic steatohepatitis (NASH) and oral lichen planus: a rare occurrence. Int J Oral Maxillofac Surg 2011;40:553-6. [PMID: 21146362 DOI: 10.1016/j.ijom.2010.11.001] [Reference Citation Analysis]
101 Edens MA, Kuipers F, Stolk RP. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obesity Reviews 2009;10:412-9. [DOI: 10.1111/j.1467-789x.2009.00594.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
102 Shi ZH, Lin LL, Feng YX, Zheng YQ. Fistular onion stalk extract reduces NF-κB expression and TNF-α secretion in steatotic HepG2 cells. Shijie Huaren Xiaohua Zazhi 2010; 18(32): 3457-3461 [DOI: 10.11569/wcjd.v18.i32.3457] [Reference Citation Analysis]
103 Wang X, Ke J, Zhu YJ, Cao B, Yin RL, Wang Y, Wei LL, Zhang LJ, Yang LY, Zhao D. Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NFκB pathway. Cell Death Discov 2021;7:236. [PMID: 34493714 DOI: 10.1038/s41420-021-00625-7] [Reference Citation Analysis]
104 Yuan Y, Naito H, Jia X, Kitamori K, Nakajima T. Combination of Hypertension Along with a High Fat and Cholesterol Diet Induces Severe Hepatic Inflammation in Rats via a Signaling Network Comprising NF-κB, MAPK, and Nrf2 Pathways. Nutrients 2017;9:E1018. [PMID: 28906458 DOI: 10.3390/nu9091018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
105 Videla LA, Pettinelli P. Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity. PPAR Res. 2012;2012:107434. [PMID: 23304111 DOI: 10.1155/2012/107434] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
106 Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol. 2008;103:1036-1042. [PMID: 18177455 DOI: 10.1111/j.1572-0241.2007.01709.x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 134] [Article Influence: 9.0] [Reference Citation Analysis]
107 Mas E, Danjoux M, Garcia V, Carpentier S, Ségui B, Levade T. IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. PLoS One. 2009;4:e7929. [PMID: 19936233 DOI: 10.1371/journal.pone.0007929] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 4.4] [Reference Citation Analysis]
108 Ore A, Akinloye OA. Oxidative Stress and Antioxidant Biomarkers in Clinical and Experimental Models of Non-Alcoholic Fatty Liver Disease. Medicina (Kaunas) 2019;55:E26. [PMID: 30682878 DOI: 10.3390/medicina55020026] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 15.0] [Reference Citation Analysis]
109 Mohamed SH, Shahat AA, Mohamed MR, Khalil WKB, Salem AM, Farrag ARH, Ahmed HH. Camellia sinesis leaves extract ameliorates high fat diet-induced nonalcoholic steatohepatitis in rats: analysis of potential mechanisms. J Pharm Investig 2021;51:183-97. [DOI: 10.1007/s40005-020-00500-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Mridha AR, Haczeyni F, Yeh MM, Haigh WG, Ioannou GN, Barn V, Ajamieh H, Adams L, Hamdorf JM, Teoh NC, Farrell GC. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival. Clin Sci (Lond). 2017;131:2145-2159. [PMID: 28687713 DOI: 10.1042/cs20160838] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 7.6] [Reference Citation Analysis]
111 Fujimoto M, Tsuneyama K, Kainuma M, Sekiya N, Goto H, Takano Y, Terasawa K, Selmi C, Gershwin ME, Shimada Y. Evidence-Based Efficacy of Kampo Formulas in a Model of Non Alcoholic Fatty Liver. Exp Biol Med (Maywood) 2008;233:328-37. [DOI: 10.3181/0707-rm-207] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
112 Gadd VL, Skoien R, Powell EE, Fagan KJ, Winterford C, Horsfall L, Irvine K, Clouston AD. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology. 2014;59:1393-1405. [PMID: 24254368 DOI: 10.1002/hep.26937] [Cited by in Crossref: 197] [Cited by in F6Publishing: 186] [Article Influence: 24.6] [Reference Citation Analysis]
113 Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87:1-16. [PMID: 16436109 DOI: 10.1111/j.0959-9673.2006.00465.x] [Cited by in Crossref: 487] [Cited by in F6Publishing: 482] [Article Influence: 30.4] [Reference Citation Analysis]
114 Wang YL, Liu LJ, Zhao WH, Li JX. Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med. 2015;2015:715638. [PMID: 26221176 DOI: 10.1155/2015/715638] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
115 Jichitu A, Bungau S, Stanescu AMA, Vesa CM, Toma MM, Bustea C, Iurciuc S, Rus M, Bacalbasa N, Diaconu CC. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics (Basel) 2021;11:689. [PMID: 33921359 DOI: 10.3390/diagnostics11040689] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
116 Tokushige K, Hashimoto E, Tsuchiya N, Kaneda H, Taniai M, Shiratori K. Clinical significance of soluble TNF receptor in Japanese patients with non-alcoholic steatohepatitis. Alcohol Clin Exp Res. 2005;29:298S-303S. [PMID: 16385240 DOI: 10.1097/01.alc.0000191810.46000.37] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
117 Gao Y, Liu Y, Yang M, Guo X, Zhang M, Li H, Li J, Zhao J. IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis. Oncotarget. 2016;7:33649-33661. [PMID: 27172901 DOI: 10.18632/oncotarget.9259] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
118 Arias-Loste MT, Fábrega E, López-Hoyos M, Crespo J. The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease. Biomed Res Int 2015;2015:319745. [PMID: 26491664 DOI: 10.1155/2015/319745] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
119 Su YM, Lv GR, Xie JX, Wang ZH, Lin HT. Maternal hypoxia increases the susceptibility of adult rat male offspring to high-fat diet-induced nonalcoholic fatty liver disease. Endocrinology 2013;154:4377-87. [PMID: 24002036 DOI: 10.1210/en.2012-1683] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
120 Machado MV, Cortez-Pinto H. Cell death and nonalcoholic steatohepatitis: where is ballooning relevant? Expert Rev Gastroenterol Hepatol. 2011;5:213-222. [PMID: 21476916 DOI: 10.1586/egh.11.16] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
121 Wang ZL, Xia B, Shrestha U, Jiang L, Ma CW, Chen Q, Chen H, Hu ZG. Correlation between adiponectin polymorphisms and non-alcoholic fatty liver disease with or without metabolic syndrome in Chinese population. J Endocrinol Invest. 2008;31:1086-1091. [PMID: 19246975 DOI: 10.1007/bf03345657] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
122 Durán-Vian C, Arias-Loste MT, Hernández JL, Fernández V, González M, Iruzubieta P, Rasines L, González-Vela C, Vaqué JP, Blanco R, Crespo J, González-López MA. High prevalence of non-alcoholic fatty liver disease among hidradenitis suppurativa patients independent of classic metabolic risk factors. J Eur Acad Dermatol Venereol 2019;33:2131-6. [PMID: 31260574 DOI: 10.1111/jdv.15764] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
123 dos Santos Carvalho J, Cardoso Guimarães Vasconcelos AC, Herlany Pereira Alves E, dos Santos Carvalho A, da Silva FRP, de Carvalho França LF, de Pádua Rocha Nóbrega Neto A, Di Lenardo D, de Souza LKM, Barbosa ALDR, Medeiros JR, de Oliveira JS, Vasconcelos DFP. Steatosis caused by experimental periodontitis is reversible after removal of ligature in rats. J Periodont Res 2017;52:883-92. [DOI: 10.1111/jre.12459] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
124 Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, Pan CS, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Stanley TL, Chung RT, Grinspoon SK. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight 2020;5:140134. [PMID: 32701508 DOI: 10.1172/jci.insight.140134] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
125 Manco M, Fernandez-real JM, Equitani F, Vendrell J, Valera Mora ME, Nanni G, Tondolo V, Calvani M, Ricart W, Castagneto M, Mingrone G. Effect of Massive Weight Loss on Inflammatory Adipocytokines and the Innate Immune System in Morbidly Obese Women. The Journal of Clinical Endocrinology & Metabolism 2007;92:483-90. [DOI: 10.1210/jc.2006-0960] [Cited by in Crossref: 112] [Cited by in F6Publishing: 105] [Article Influence: 7.0] [Reference Citation Analysis]
126 García-Compeán D, González-González JA, Lavalle-González FJ, González-Moreno EI, Villarreal-Pérez JZ, Maldonado-Garza HJ. Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy. Dig Dis Sci. 2016;61:371-380. [PMID: 26462490 DOI: 10.1007/s10620-015-3907-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
127 Kawaratani H, Tsujimoto T, Kitazawa T, Kitade M, Yoshiji H, Uemura M, Fukui H. Innate immune reactivity of the liver in rats fed a choline-deficient L-amino-acid-defined diet. World J Gastroenterol 2008; 14(43): 6655-6661 [PMID: 19034968 DOI: 10.3748/wjg.14.6655] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
128 Eguchi A, Wree A, Feldstein AE. Biomarkers of liver cell death. J Hepatol. 2014;60:1063-1074. [PMID: 24412608 DOI: 10.1016/j.jhep.2013.12.026] [Cited by in Crossref: 109] [Cited by in F6Publishing: 105] [Article Influence: 13.6] [Reference Citation Analysis]
129 Lu S, Wang Y, Liu J. TNF-α signaling in non-alcoholic steatohepatitis and targeted therapies. J Genet Genomics 2021:S1673-8527(21)00337-4. [PMID: 34757037 DOI: 10.1016/j.jgg.2021.09.009] [Reference Citation Analysis]
130 Asano T, Watanabe K, Kubota N, Gunji T, Omata M, Kadowaki T, Ohnishi S. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol. 2009;24:1669-1676. [PMID: 19788607 DOI: 10.1111/j.1440-1746.2009.06039.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.0] [Reference Citation Analysis]
131 Fujii H, Kawada N. Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol. 2012;47:215-225. [PMID: 22310735 DOI: 10.1007/s00535-012-0527-x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 99] [Article Influence: 9.9] [Reference Citation Analysis]
132 Ghadieh HE, Muturi HT, Najjar SM. Exenatide Prevents Diet-induced Hepatocellular Injury in A CEACAM1-Dependent Mechanism. J Diabetes Treat 2017;2017. [PMID: 29431170 DOI: 10.29011/2574.7568.000033] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
133 Diesen DL, Kuo PC. Nitric oxide and redox regulation in the liver: Part I. General considerations and redox biology in hepatitis. J Surg Res. 2010;162:95-109. [PMID: 20444470 DOI: 10.1016/j.jss.2009.09.019] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 4.3] [Reference Citation Analysis]
134 Sarna LK, Siow YL, O K. The CBS/CSE system: a potential therapeutic target in NAFLD? Can J Physiol Pharmacol 2015;93:1-11. [PMID: 25493326 DOI: 10.1139/cjpp-2014-0394] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
135 Lu Q, Tian X, Wu H, Huang J, Li M, Mei Z, Zhou L, Xie H, Zheng S. Metabolic Changes of Hepatocytes in NAFLD. Front Physiol 2021;12:710420. [PMID: 34526911 DOI: 10.3389/fphys.2021.710420] [Reference Citation Analysis]
136 Yunianingtias D, Volker D. Nutritional aspects of non-alcoholic steatohepatitis treatment. Nutrition & Dietetics 2006;63:79-90. [DOI: 10.1111/j.1747-0080.2006.00054.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
137 Dossi CG, Tapia GS, Espinosa A, Videla LA, D'Espessailles A. Reversal of high-fat diet-induced hepatic steatosis by n-3 LCPUFA: role of PPAR-α and SREBP-1c. J Nutr Biochem 2014;25:977-84. [PMID: 24993917 DOI: 10.1016/j.jnutbio.2014.04.011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
138 Hu Y, Liu X. Protective effects of SP600125 in a diet-induced rat model of non-alcoholic steatohepatitis. Scandinavian Journal of Gastroenterology 2009;44:1356-62. [DOI: 10.3109/00365520903312441] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
139 Wang X, Shang X, Cui Y, Zhao X, Zhang Y, Xie M. Osthole inhibits inflammatory cytokine release through PPAR α / γ -mediated mechanisms in LPS-stimulated 3T3-L1 adipocytes. Immunopharmacology and Immunotoxicology 2015;37:185-92. [DOI: 10.3109/08923973.2015.1009997] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
140 Gormaz JG, Rodrigo R, Videla LA, Beems M. Biosynthesis and bioavailability of long-chain polyunsaturated fatty acids in non-alcoholic fatty liver disease. Progress in Lipid Research 2010;49:407-19. [DOI: 10.1016/j.plipres.2010.05.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
141 Auguet T, Berlanga A, Guiu-Jurado E, Martinez S, Porras JA, Aragonès G, Sabench F, Hernandez M, Aguilar C, Sirvent JJ, Del Castillo D, Richart C. Altered fatty acid metabolism-related gene expression in liver from morbidly obese women with non-alcoholic fatty liver disease. Int J Mol Sci 2014;15:22173-87. [PMID: 25474087 DOI: 10.3390/ijms151222173] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
142 Ko JS. Nonalcoholic Fatty Liver Disease. Korean J Gastroenterol 2010;56:6. [DOI: 10.4166/kjg.2010.56.1.6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
143 Naik A, Belič A, Zanger UM, Rozman D. Molecular Interactions between NAFLD and Xenobiotic Metabolism. Front Genet 2013;4:2. [PMID: 23346097 DOI: 10.3389/fgene.2013.00002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
144 Qin Y, Tian YP. Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats. Lipids Health Dis 2010;9:78. [PMID: 20653983 DOI: 10.1186/1476-511X-9-78] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
145 Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 2012; 18(8): 727-735 [PMID: 22371632 DOI: 10.3748/wjg.v18.i8.727] [Cited by in CrossRef: 193] [Cited by in F6Publishing: 177] [Article Influence: 19.3] [Reference Citation Analysis]
146 Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005;172:899-905. [PMID: 15795412 DOI: 10.1503/cmaj.045232] [Cited by in Crossref: 330] [Cited by in F6Publishing: 313] [Article Influence: 19.4] [Reference Citation Analysis]
147 Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. [PMID: 22110476 DOI: 10.1155/2012/145754] [Cited by in Crossref: 114] [Cited by in F6Publishing: 116] [Article Influence: 10.4] [Reference Citation Analysis]
148 Ghosh S, Kaw M, Patel PR, Ledford KJ, Bowman TA, McInerney MF, Erickson SK, Bourey RE, Najjar SM. Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis. Hepat Med 2010;2010:69-78. [PMID: 21949477 DOI: 10.2147/HMER.S8902] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 0.3] [Reference Citation Analysis]
149 Cazanave SC, Sanyal AJ. Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease. In: Ntambi JM, editor. Hepatic De Novo Lipogenesis and Regulation of Metabolism. Cham: Springer International Publishing; 2016. pp. 101-29. [DOI: 10.1007/978-3-319-25065-6_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
150 Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, Sanyal AJ. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2008;134:568-576. [PMID: 18082745 DOI: 10.1053/j.gastro.2007.10.039] [Cited by in Crossref: 383] [Cited by in F6Publishing: 356] [Article Influence: 25.5] [Reference Citation Analysis]
151 Goel A, Gupta M, Aggarwal R. Gut microbiota and liver disease. J Gastroenterol Hepatol 2014;29:1139-48. [PMID: 24547986 DOI: 10.1111/jgh.12556] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
152 Borgmann S, Bayer A, König W, Ambrosch A, Kraus J. Contrasting Effects of Long-Term Treatment with IFN-γ in Endothelial Cells: Increase in IL-6 Secretion Versus Decrease in IL-8 Secretion, NF-κB, and AP-1 Activation. Endothelium 2009;9:173-8. [DOI: 10.1080/10623320213636] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
153 Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 2009;116:539-564. [PMID: 19243311 DOI: 10.1042/cs20080253] [Cited by in Crossref: 160] [Cited by in F6Publishing: 74] [Article Influence: 12.3] [Reference Citation Analysis]
154 Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, Barzin M, Orang E. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(35): 12566-12573 [PMID: 25253959 DOI: 10.3748/wjg.v20.i35.12566] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
155 Schattenberg JM, Schuchmann M. Diabetes and apoptosis: liver. Apoptosis 2009;14:1459-71. [PMID: 19544096 DOI: 10.1007/s10495-009-0366-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
156 Lai HS, Lin WH, Chen PR, Wu HC, Lee PH, Chen WJ. Effects of a high-fiber diet on hepatocyte apoptosis and liver regeneration after partial hepatectomy in rats with fatty liver. JPEN J Parenter Enteral Nutr. 2005;29:401-407. [PMID: 16224031 DOI: 10.1177/0148607105029006401] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
157 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2003; 11(7): 1043-1045 [DOI: 10.11569/wcjd.v11.i7.1043] [Reference Citation Analysis]
158 Gonzalez Rozas M, Hernanz Roman L, Gonzalez DG, Pérez-Castrillón JL. Panhypopituitarism due to Absence of the Pituitary Stalk: A Rare Aetiology of Liver Cirrhosis. Case Rep Endocrinol 2016;2016:9071097. [PMID: 27213061 DOI: 10.1155/2016/9071097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
159 Ciavarella A, Gnocchi D, Custodero C, Lenato GM, Fiore G, Sabbà C, Mazzocca A. Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease. Thromb Res 2021;198:139-50. [PMID: 33340925 DOI: 10.1016/j.thromres.2020.12.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
160 Cazzo E, Pareja JC, Chaim EA. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Med J 2017;135:277-95. [DOI: 10.1590/1516-3180.2016.0306311216] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
161 Te Sligte K, Bourass I, Sels JP, Driessen A, Stockbrugger RW, Koek GH. Non-alcoholic steatohepatitis: review of a growing medical problem. Eur J Intern Med. 2004;15:10-21. [PMID: 15066643 DOI: 10.1016/j.ejim.2003.12.008] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 3.8] [Reference Citation Analysis]
162 Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver. 2012;6:149-171. [PMID: 22570745 DOI: 10.5009/gnl.2012.6.2.149] [Cited by in Crossref: 247] [Cited by in F6Publishing: 231] [Article Influence: 24.7] [Reference Citation Analysis]
163 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 17.0] [Reference Citation Analysis]
164 Wong VW, Wong GL, Tsang SW, Hui AY, Chan AW, Choi PC, So WY, Tse AM, Chan FK, Sung JJ. Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. J Gastroenterol Hepatol. 2008;23:914-921. [PMID: 18565022 DOI: 10.1111/j.1440-1746.2008.05344.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
165 Baumgardner JN, Shankar K, Hennings L, Albano E, Badger TM, Ronis MJ. N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J Nutr. 2008;138:1872-1879. [PMID: 18806095 DOI: 10.1093/jn/138.10.1872] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 4.6] [Reference Citation Analysis]
166 Videla LA, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med. 2004;37:1499-1507. [PMID: 15454290 DOI: 10.1016/j.freeradbiomed.2004.06.033] [Cited by in Crossref: 165] [Cited by in F6Publishing: 161] [Article Influence: 9.7] [Reference Citation Analysis]
167 Grønbaek H, Thomsen KL, Rungby J, Schmitz O, Vilstrup H. Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. Expert Rev Gastroenterol Hepatol. 2008;2:705-711. [PMID: 19072347 DOI: 10.1586/17474124.2.5.705] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
168 Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, Kitamura N, Toda K, Kaneko T, Horie Y, Han JY, Kato S, Shimoda M, Oike Y, Tomizawa M, Makino S, Ohkura T, Saito H, Kumagai N, Nagata H, Ishii H, Hibi T. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 2006;55:415-424. [PMID: 16174657 DOI: 10.1136/gut.2005.071118] [Cited by in Crossref: 283] [Cited by in F6Publishing: 280] [Article Influence: 16.6] [Reference Citation Analysis]
169 Brookes MJ, Cooper BT. Hypertension and fatty liver: guilty by association? J Hum Hypertens. 2007;21:264-270. [PMID: 17273155 DOI: 10.1038/sj.jhh.1002148] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
170 Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Digestive and Liver Disease 2009;41:615-25. [DOI: 10.1016/j.dld.2009.01.004] [Cited by in Crossref: 174] [Cited by in F6Publishing: 174] [Article Influence: 13.4] [Reference Citation Analysis]
171 Pessayre D, Fromenty B, Mansouri A. Mitochondrial injury in steatohepatitis. Eur J Gastroenterol Hepatol. 2004;16:1095-1105. [PMID: 15489566 DOI: 10.1097/00042737-200411000-00003] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 5.8] [Reference Citation Analysis]
172 Wang Z, Zhu F. Minichromosome maintenance protein 7 regulates phagocytosis in kuruma shrimp Marsupenaeus japonicas against white spot syndrome virus. Fish Shellfish Immunol 2016;55:293-303. [PMID: 27276115 DOI: 10.1016/j.fsi.2016.06.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
173 Kammoun HL, Allen TL, Henstridge DC, Kraakman MJ, Peijs L, Rose-John S, Febbraio MA. Over-expressing the soluble gp130-Fc does not ameliorate methionine and choline deficient diet-induced non alcoholic steatohepatitis in mice. PLoS One 2017;12:e0179099. [PMID: 28632778 DOI: 10.1371/journal.pone.0179099] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
174 Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009; 15(3): 280-288 [PMID: 19140227 DOI: 10.3748/wjg.15.280] [Cited by in CrossRef: 196] [Cited by in F6Publishing: 180] [Article Influence: 15.1] [Reference Citation Analysis]
175 Sarr O, Blake A, Thompson JA, Zhao L, Rabicki K, Walsh JC, Welch I, Regnault TR. The differential effects of low birth weight and Western diet consumption upon early life hepatic fibrosis development in guinea pig. J Physiol 2016;594:1753-72. [PMID: 26662996 DOI: 10.1113/JP271777] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
176 Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. J Lipid Res 2011;52:593-617. [PMID: 21245030 DOI: 10.1194/jlr.R008896] [Cited by in Crossref: 83] [Cited by in F6Publishing: 55] [Article Influence: 7.5] [Reference Citation Analysis]
177 Negash AA, Gale M Jr. Hepatitis regulation by the inflammasome signaling pathway. Immunol Rev. 2015;265:143-155. [PMID: 25879290 DOI: 10.1111/imr.12279] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
178 Ozturk Y, Soylu OB. Fatty liver in childhood. World J Hepatol 2014; 6(1): 33-40 [PMID: 24653792 DOI: 10.4254/wjh.v6.i1.33] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
179 Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. J Biol Chem. 2012;287:40161-40172. [PMID: 23066023 DOI: 10.10747/jbc.M112.417014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Ruiz AG, Casafont F, Crespo J, Cayón A, Mayorga M, Estebanez A, Fernadez-Escalante JC, Pons-Romero F. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg. 2007;17:1374-1380. [PMID: 18000721 DOI: 10.1007/s11695-007-9243-7] [Cited by in Crossref: 186] [Cited by in F6Publishing: 180] [Article Influence: 13.3] [Reference Citation Analysis]
181 Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008;14:72-81. [PMID: 18218340 DOI: 10.1016/j.molmed.2007.12.003] [Cited by in Crossref: 293] [Cited by in F6Publishing: 288] [Article Influence: 20.9] [Reference Citation Analysis]
182 Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial Effects of Tumor Necrosis Factor-alpha Inhibition by Pentoxifylline on Clinical, Biochemical, and Metabolic Parameters of Patients with Nonalcoholic Steatohepatitis. Am J Gastroenterology 2004;99:1946-52. [DOI: 10.1111/j.1572-0241.2004.40220.x] [Cited by in Crossref: 141] [Cited by in F6Publishing: 142] [Article Influence: 7.8] [Reference Citation Analysis]
183 Huang H, Zhang X, Li J. Protective effect of oroxylin A against lipopolysaccharide and/or D-galactosamine-induced acute liver injury in mice. J Surg Res 2015;195:522-8. [PMID: 25818981 DOI: 10.1016/j.jss.2015.01.047] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
184 Aghazadeh S, Amini R, Yazdanparast R, Ghaffari SH. Anti-apoptotic and anti-inflammatory effects of Silybum marianum in treatment of experimental steatohepatitis. Exp Toxicol Pathol 2011;63:569-74. [PMID: 20471811 DOI: 10.1016/j.etp.2010.04.009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
185 Matthew Morris E, Fletcher JA, Thyfault JP, Scott Rector R. The role of angiotensin II in nonalcoholic steatohepatitis. Molecular and Cellular Endocrinology 2013;378:29-40. [DOI: 10.1016/j.mce.2012.04.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
186 Mas E, Danjoux M, Garcia V, Carpentier S, Ségui B, Levade T. The pro-inflammatory action of tumour necrosis factor-α in non-alcoholic steatohepatitis is independent of the NSMAF gene product. Dig Liver Dis 2013;45:147-54. [PMID: 23044079 DOI: 10.1016/j.dld.2012.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
187 Erbaş O, Akseki HS, Aktuğ H, Taşkıran D. Low-grade chronic inflammation induces behavioral stereotypy in rats. Metab Brain Dis 2015;30:739-46. [DOI: 10.1007/s11011-014-9630-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
188 Barbagallo I, Li Volti G, Raffaele M, Distefano A, Palmeri R, Parafati L, Licari M, Zingales V, Avola R, Vanella L. The effects of olive leaf extract from a Sicilian cultivar in an experimental model of hepatic steatosis. Rend Fis Acc Lincei 2017;28:643-50. [DOI: 10.1007/s12210-017-0649-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
189 Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020;41. [PMID: 31629366 DOI: 10.1210/endrev/bnz009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 30.0] [Reference Citation Analysis]
190 Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, Kitamura N, Toda K, Kaneko T, Horie Y. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 2006;55:415-424. [PMID: 16174657 DOI: 10.1136/gut.2005. 071118] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
191 Torres N, Torre-villalvazo I, R Tovar A. Future directions in reducing hepatic lipotoxicity. Future Lipidology 2006;1:331-41. [DOI: 10.2217/17460875.1.3.331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
192 Yalniz M, Bahçecioğlu IH, Kuzu N, Celebi S, Ataseven H, Ustündağ B, Ozercan IH, Sahin K. Amelioration of steatohepatitis with pentoxifylline in a novel nonalcoholic steatohepatitis model induced by high-fat diet. Dig Dis Sci 2007;52:2380-6. [PMID: 17415655 DOI: 10.1007/s10620-006-9194-1] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
193 Baranova A, Schlauch K, Gowder S, Collantes R, Chandhoke V, Younossi ZM. Microarray technology in the study of obesity and non-alcoholic fatty liver disease. Liver Int. 2005;25:1091-1096. [PMID: 16343057 DOI: 10.1111/j.1478-3231.2005.01183.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
194 Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab. 2004;30:121-138. [PMID: 15223984 DOI: 10.1016/s1262-3636(07)70098-8] [Cited by in Crossref: 177] [Cited by in F6Publishing: 67] [Article Influence: 9.8] [Reference Citation Analysis]
195 Videla LA, Tapia G, Rodrigo R, Pettinelli P, Haim D, Santibañez C, Araya AV, Smok G, Csendes A, Gutierrez L, Rojas J, Castillo J, Korn O, Maluenda F, Díaz JC, Rencoret G, Poniachik J. Liver NF-κB and AP-1 DNA Binding in Obese Patients. Obesity 2009;17:973-9. [DOI: 10.1038/oby.2008.601] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 6.5] [Reference Citation Analysis]
196 Ma X, Li Z. Pathogenesis of nonalcoholic steatohepatitis (NASH). Chin Dig Dis 2006;7:7-11. [DOI: 10.1111/j.1443-9573.2006.00237.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
197 Eliades M, Spyrou E. Vitamin D: A new player in non-alcoholic fatty liver disease? World J Gastroenterol 2015; 21(6): 1718-1727 [PMID: 25684936 DOI: 10.3748/wjg.v21.i6.1718] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 71] [Article Influence: 11.7] [Reference Citation Analysis]
198 Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol. 2007;46:1104-1110. [PMID: 17395331 DOI: 10.1016/j.jhep.2007.01.028] [Cited by in Crossref: 118] [Cited by in F6Publishing: 105] [Article Influence: 7.9] [Reference Citation Analysis]
199 Hijona E, Hijona L, Arenas JI, Bujanda L. Inflammatory mediators of hepatic steatosis. Mediators Inflamm 2010;2010:837419. [PMID: 20300479 DOI: 10.1155/2010/837419] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 4.7] [Reference Citation Analysis]
200 Song Z, Joshi-Barve S, Barve S, McClain CJ. Advances in alcoholic liver disease. Curr Gastroenterol Rep 2004;6:71-6. [PMID: 14720457 DOI: 10.1007/s11894-004-0029-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
201 Najjar SM, Russo L. CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH). Semin Immunopathol. 2014;36:55-71. [PMID: 24258517 DOI: 10.1007/s00281-013-0407-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
202 Pérez-Carreras M, Del Hoyo P, Martín MA, Rubio JC, Martín A, Castellano G, Colina F, Arenas J, Solis-Herruzo JA. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003;38:999-1007. [PMID: 14512887 DOI: 10.1002/hep.1840380426] [Cited by in Crossref: 301] [Cited by in F6Publishing: 135] [Article Influence: 15.8] [Reference Citation Analysis]
203 Hanje AJ, Fortune B, Song M, Hill D, McClain C. The use of selected nutrition supplements and complementary and alternative medicine in liver disease. Nutr Clin Pract 2006;21:255-72. [PMID: 16772543 DOI: 10.1177/0115426506021003255] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
204 Wu SD, Li L, Wang JY. Ursodeoxycholic acid for nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2012;24:1247-1253. [PMID: 22864259 DOI: 10.1097/meg.0b013e3283572ec0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
205 Fischer R, Kontermann RE, Pfizenmaier K. Selective Targeting of TNF Receptors as a Novel Therapeutic Approach. Front Cell Dev Biol 2020;8:401. [PMID: 32528961 DOI: 10.3389/fcell.2020.00401] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
206 Nawaz R, Zahid S, Idrees M, Rafique S, Shahid M, Ahad A, Amin I, Almas I, Afzal S. HCV-induced regulatory alterations of IL-1β, IL-6, TNF-α, and IFN-ϒ operative, leading liver en-route to non-alcoholic steatohepatitis. Inflamm Res 2017;66:477-86. [PMID: 28285394 DOI: 10.1007/s00011-017-1029-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
207 Pan MH, Lai CS, Tsai ML, Ho CT. Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. Mol Nutr Food Res. 2014;58:147-171. [PMID: 24302567 DOI: 10.1002/mnfr.201300522] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 6.6] [Reference Citation Analysis]
208 Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjøro K, Aukrust P. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. Journal of Hepatology 2006;44:1167-74. [DOI: 10.1016/j.jhep.2006.02.011] [Cited by in Crossref: 347] [Cited by in F6Publishing: 348] [Article Influence: 21.7] [Reference Citation Analysis]
209 Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, Papa G, Rabuazzo AM, Purrello F. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis. 2008;40:194-199. [PMID: 18054848 DOI: 10.1016/j.dld.2007.10.003] [Cited by in Crossref: 191] [Cited by in F6Publishing: 185] [Article Influence: 12.7] [Reference Citation Analysis]
210 Lamadrid P, Alonso-Peña M, San Segundo D, Arias-Loste M, Crespo J, Lopez-Hoyos M. Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity. Front Immunol 2021;12:651728. [PMID: 33859644 DOI: 10.3389/fimmu.2021.651728] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
211 Kołodziejski PA, Pruszyńska-oszmałek E, Strowski MZ, Nowak KW. Long-term obestatin treatment of mice type 2 diabetes increases insulin sensitivity and improves liver function. Endocrine 2017;56:538-50. [DOI: 10.1007/s12020-017-1309-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
212 Ono M, Okamoto N, Saibara T. The latest idea in NAFLD/NASH pathogenesis. Clin J Gastroenterol. 2010;3:263-270. [PMID: 26190482 DOI: 10.1007/s12328-010-0182-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
213 Gerges SH, Wahdan SA, Elsherbiny DA, El-demerdash E. Diosmin ameliorates inflammation, insulin resistance, and fibrosis in an experimental model of non-alcoholic steatohepatitis in rats. Toxicology and Applied Pharmacology 2020;401:115101. [DOI: 10.1016/j.taap.2020.115101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
214 Rouvinen-Watt K, Pal C, Martin T, Harris L, Astatkie T, Kryzskaya D, Kärjä V, Mustonen AM, Tammi R, Tammi M, Nieminen P. Evidence of endoplasmic reticulum stress and liver inflammation in the American mink Neovison vison with benign hepatic steatosis. J Comp Physiol B 2014;184:913-27. [PMID: 25079677 DOI: 10.1007/s00360-014-0845-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
215 Zhang SR, Fan XM. Ghrelin-ghrelin O-acyltransferase system in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21(11): 3214-3222 [PMID: 25805927 DOI: 10.3748/wjg.v21.i11.3214] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
216 Armutcu F, Akyol S, Ucar F, Erdogan S, Akyol O. Markers in Nonalcoholic Steatohepatitis. Elsevier; 2013. pp. 67-125. [DOI: 10.1016/b978-0-12-407680-8.00004-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, Zeuzem S, Hein J, Berg T; NASH Study Group. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52:472-9. [PMID: 20683947 DOI: 10.1002/hep.23727] [Cited by in Crossref: 202] [Cited by in F6Publishing: 175] [Article Influence: 16.8] [Reference Citation Analysis]
218 Méndez-Sánchez N, Arrese M, Zamora-Valdés D, Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int. 2007;27:423-433. [PMID: 17403181 DOI: 10.1111/j.1478-3231.2007.01483.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 120] [Article Influence: 7.7] [Reference Citation Analysis]
219 Sánchez-Lozada LG, Mu W, Roncal C, Sautin YY, Abdelmalek M, Reungjui S, Le M, Nakagawa T, Lan HY, Yu X, Johnson RJ. Comparison of free fructose and glucose to sucrose in the ability to cause fatty liver. Eur J Nutr 2010;49:1-9. [PMID: 19626358 DOI: 10.1007/s00394-009-0042-x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
220 Takahashi H, Suzuki M, Ikeda H, Kobayashi M, Sase S, Yotsuyanagi H, Maeyama S, Iino S, Itoh F. Evaluation of quantitative portal venous, hepatic arterial, and total hepatic tissue blood flow using xenon CT in alcoholic liver cirrhosis: comparison with liver cirrhosis C. Alcohol Clin Exp Res. 2007;31:S43-S48. [PMID: 17331165 DOI: 10.1111/j.1530-0277.2006.00285.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
221 Banks SE, Riley TR, Naides SJ. Musculoskeletal complaints and serum autoantibodies associated with chronic hepatitis C and nonalcoholic fatty liver disease. Dig Dis Sci. 2007;52:1177-1182. [PMID: 17387612 DOI: 10.1007/s10620-006-9109-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
222 Malaguarnera L, Di Rosa M, Zambito AM, dell’Ombra N, Di Marco R, Malaguarnera M. Potential role of chitotriosidase gene in nonalcoholic fatty liver disease evolution. Am J Gastroenterol. 2006;101:2060-2069. [PMID: 16848812 DOI: 10.1111/j.1572-0241.2006.00680.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 3.1] [Reference Citation Analysis]
223 Zhang ZB, Sun XQ, Qian F, Xue BY. Role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2011; 19(19): 2036-2042 [DOI: 10.11569/wcjd.v19.i19.2036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
224 Oh JM, Choi JM, Lee JY, Oh SJ, Kim HC, Kim BH, Ma JY, Kim SK. Effects of palmitic acid on TNF-α-induced cytotoxicity in SK-Hep-1 cells. Toxicology in Vitro 2012;26:783-90. [DOI: 10.1016/j.tiv.2012.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
225 Harrison SA, Di Bisceglie AM. Advances in the Understanding and Treatment of Nonalcoholic Fatty Liver Disease: . Drugs 2003;63:2379-94. [DOI: 10.2165/00003495-200363220-00001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
226 Magdy YM, El-kharashi OA, Nabih ES, Shaker SM, Abd-elaziz LF, Aboul-fotouh S. Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress. Biomedicine & Pharmacotherapy 2017;85:225-38. [DOI: 10.1016/j.biopha.2016.10.098] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
227 Nozaki Y, Saibara T, Nemoto Y, Ono M, Akisawa N, Iwasaki S, Hayashi Y, Hiroi M, Enzan H, Onishi S. Polymorphisms of Interleukin-1beta and beta3-Adrenergic Receptor in Japanese Patients With Nonalcoholic Steatohepatitis. Alcoholism Clin Exp Res 2004;28:106S-10S. [DOI: 10.1111/j.1530-0277.2004.tb03226.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 20] [Article Influence: 0.2] [Reference Citation Analysis]
228 Charlton M, Angulo P, Chalasani N, Merriman R, Viker K, Charatcharoenwitthaya P, Sanderson S, Gawrieh S, Krishnan A, Lindor K. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology. 2008;47:484-492. [PMID: 18220286 DOI: 10.1002/hep.22063] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 4.9] [Reference Citation Analysis]
229 Lebensztejn DM, Kowalczuk D, Tarasów E, Skiba E, Kaczmarski M. Tumor necrosis factor alpha and its soluble receptors in obese children with NAFLD. Adv Med Sci. 2010;55:74-79. [PMID: 20371430 DOI: 10.2478/v10039-010-0008-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
230 Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology. 2006;131:934-945. [PMID: 16952562 DOI: 10.1053/j.gastro.2006.05.054] [Cited by in Crossref: 241] [Cited by in F6Publishing: 229] [Article Influence: 15.1] [Reference Citation Analysis]
231 Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol. 2016;30:282-287. [PMID: 26537011 DOI: 10.1111/jdv.13456] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
232 Clemente Ricote G, García Monzón C. Estado actual de la esteatohepatitis no alcohólica. Medicina Clínica 2003;121:102-8. [DOI: 10.1016/s0025-7753(03)73870-6] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
233 Fujita N, Takei Y. Iron overload in nonalcoholic steatohepatitis. Adv Clin Chem. 2011;55:105-132. [PMID: 22126026 DOI: 10.1016/b978-0-12-387042-1.00006-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
234 S??nchez-mu??oz D, Romero-g??mez M, Gonz??lez-escribano MF, Torres B, Castellano-megias VM, G??mez-izquierdo L, Aguilar-reina J, Nu??ez-roldan A. Tumour necrosis factor alpha polymorphisms are not involved in the development of steatosis in chronic hepatitis C: . European Journal of Gastroenterology & Hepatology 2004;16:761-5. [DOI: 10.1097/01.meg.0000108368.19243.97] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
235 Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Biology and Medicine 2012;52:59-69. [DOI: 10.1016/j.freeradbiomed.2011.10.003] [Cited by in Crossref: 539] [Cited by in F6Publishing: 519] [Article Influence: 53.9] [Reference Citation Analysis]
236 Rufinatscha K, Ress C, Folie S, Haas S, Salzmann K, Moser P, Dobner J, Weiss G, Iruzubieta P, Arias-Loste MT, Crespo J, Tilg H, Kaser S. Metabolic effects of reduced growth hormone action in fatty liver disease. Hepatol Int 2018;12:474-81. [PMID: 30206761 DOI: 10.1007/s12072-018-9893-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
237 Zhang LJ, Yu JP, Li D, Huang YH, Chen ZX, Wang XZ. Effects of cytokines on carbon tetrachloride-induced hepatic fibrogenesis in rats. World J Gastroenterol 2004; 10(1): 77-81 [PMID: 14695773 DOI: 10.3748/wjg.v10.i1.77] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
238 Ponziani FR, Pecere S, Gasbarrini A, Ojetti V. Physiology and pathophysiology of liver lipid metabolism. Expert Review of Gastroenterology & Hepatology 2015;9:1055-67. [DOI: 10.1586/17474124.2015.1056156] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
239 Siebler J, Galle PR. Treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2006; 12(14): 2161-2167 [PMID: 16610015 DOI: 10.3748/wjg.v12.i14.2161] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
240 Aitbaev KA, Murkamilov IT, Fomin VV. [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation]. Ter Arkh 2017;89:120-8. [PMID: 28914862 DOI: 10.17116/terarkh2017898120-128] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
241 Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179-185. [PMID: 22297845 DOI: 10.1038/nature10809] [Cited by in Crossref: 1446] [Cited by in F6Publishing: 1384] [Article Influence: 144.6] [Reference Citation Analysis]
242 Ravi Kanth VV, Sasikala M, Sharma M, Rao PN, Reddy DN. Genetics of non-alcoholic fatty liver disease: From susceptibility and nutrient interactions to management. World J Hepatol 2016; 8(20): 827-837 [PMID: 27458502 DOI: 10.4254/wjh.v8.i20.827] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
243 Gerner RR, Wieser V, Moschen AR, Tilg H. Metabolic inflammation: role of cytokines in the crosstalk between adipose tissue and liver. Can J Physiol Pharmacol. 2013;91:867-872. [PMID: 24117253 DOI: 10.1139/cjpp-2013-0050] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
244 Gjorgjieva M, Mithieux G, Rajas F. Hepatic stress associated with pathologies characterized by disturbed glucose production. Cell Stress 2019;3:86-99. [PMID: 31225503 DOI: 10.15698/cst2019.03.179] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
245 Gochee PA, Jonsson JR, Clouston AD, Pandeya N, Purdie DM, Powell EE. Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1. J Gastroenterol Hepatol. 2003;18:386-392. [PMID: 12653886 DOI: 10.1046/j.1440-1746.2003.02984.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 2.9] [Reference Citation Analysis]
246 Kuo CF, Yu KH, Luo SF, Chiu CT, Ko YS, Hwang JS, Tseng WY, Chang HC, Chen HW, See LC. Gout and risk of non-alcoholic fatty liver disease. Scand J Rheumatol 2010;39:466-71. [PMID: 20560813 DOI: 10.3109/03009741003742797] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
247 Canbakan B, Senturk H, Canbakan M, Toptas T, Tabak O, Balci H, Olgac V, Ozbay G. Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease? Biomarkers in Medicine 2010;4:205-14. [DOI: 10.2217/bmm.09.88] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
248 Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci. 2011;48:97-113. [PMID: 21875310 DOI: 10.3109/10408363.2011.596521] [Cited by in Crossref: 183] [Cited by in F6Publishing: 171] [Article Influence: 16.6] [Reference Citation Analysis]
249 Tian W, Xu H, Fang F, Chen Q, Xu Y, Shen A. Brahma-related gene 1 bridges epigenetic regulation of proinflammatory cytokine production to steatohepatitis in mice. Hepatology 2013;58:576-88. [PMID: 23281043 DOI: 10.1002/hep.26207] [Cited by in Crossref: 70] [Cited by in F6Publishing: 75] [Article Influence: 8.8] [Reference Citation Analysis]
250 Uzun H, Simsek G, Aydin S, Unal E, Karter Y, Yelmen NK, Vehid S, Curgunlu A, Kaya S. Potential effects of L-NAME on alcohol-induced oxidative stress. World J Gastroenterol 2005; 11(4): 600-604 [PMID: 15641155 DOI: 10.3748/wjg.v11.i4.600] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
251 Chitturi S, Farrell GC, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol. 2004;19:368-374. [PMID: 15012772 DOI: 10.1111/j.1440-1746.2003.03252.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 96] [Article Influence: 5.6] [Reference Citation Analysis]
252 Cesaratto L, Codarin E, Vascotto C, Leonardi A, Kelley MR, Tiribelli C, Tell G. Specific inhibition of the redox activity of ape1/ref-1 by e3330 blocks tnf-α-induced activation of IL-8 production in liver cancer cell lines. PLoS One 2013;8:e70909. [PMID: 23967134 DOI: 10.1371/journal.pone.0070909] [Cited by in Crossref: 23] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
253 Qiu L, Lin J, Ying M, Chen W, Yang J, Deng T, Chen J, Shi D, Yang JY. Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis. PLoS One. 2013;8:e73591. [PMID: 24066058 DOI: 10.1371/journal.pone.0073591] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
254 Choi Y, Abdelmegeed MA, Akbar M, Song BJ. Dietary walnut reduces hepatic triglyceride content in high-fat-fed mice via modulation of hepatic fatty acid metabolism and adipose tissue inflammation. J Nutr Biochem 2016;30:116-25. [PMID: 27012628 DOI: 10.1016/j.jnutbio.2015.12.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
255 Shanab AA, Scully P, Crosbie O, Buckley M, O’mahony L, Shanahan F, Gazareen S, Murphy E, Quigley EMM. Small Intestinal Bacterial Overgrowth in Nonalcoholic Steatohepatitis: Association with Toll-Like Receptor 4 Expression and Plasma Levels of Interleukin 8. Dig Dis Sci 2011;56:1524-34. [DOI: 10.1007/s10620-010-1447-3] [Cited by in Crossref: 119] [Cited by in F6Publishing: 116] [Article Influence: 9.9] [Reference Citation Analysis]
256 Leclercq IA, Farrell GC, Sempoux C, dela Pena A, Horsmans Y. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol. 2004;41:926-934. [PMID: 15582125 DOI: 10.1016/j.jhep.2004.08.010] [Cited by in Crossref: 147] [Cited by in F6Publishing: 137] [Article Influence: 8.6] [Reference Citation Analysis]
257 Vecchione G, Grasselli E, Cioffi F, Baldini F, Oliveira PJ, Sardão VA, Cortese K, Lanni A, Voci A, Portincasa P, Vergani L. The Nutraceutic Silybin Counteracts Excess Lipid Accumulation and Ongoing Oxidative Stress in an In Vitro Model of Non-Alcoholic Fatty Liver Disease Progression. Front Nutr 2017;4:42. [PMID: 28971098 DOI: 10.3389/fnut.2017.00042] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
258 Bluemel S, Wang Y, Lee S, Schnabl B. Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice. World J Gastroenterol 2020; 26(33): 4933-4944 [PMID: 32952340 DOI: 10.3748/wjg.v26.i33.4933] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
259 Leroux A, Ferrere G, Godie V, Cailleux F, Renoud ML, Gaudin F, Naveau S, Prévot S, Makhzami S, Perlemuter G, Cassard-Doulcier AM. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J Hepatol 2012;57:141-9. [PMID: 22425624 DOI: 10.1016/j.jhep.2012.02.028] [Cited by in Crossref: 138] [Cited by in F6Publishing: 129] [Article Influence: 13.8] [Reference Citation Analysis]
260 Harrison SA, Neuschwander-tetri BA. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clinics in Liver Disease 2004;8:861-79. [DOI: 10.1016/j.cld.2004.06.008] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 4.5] [Reference Citation Analysis]
261 Manka P, Sydor S, Wase N, Best J, Brandenburg M, Hellbeck A, Schänzer J, Vilchez-Vargas R, Link A, Figge A, Jähnert A, von Arnim U, Coombes JD, Cubero FJ, Kahraman A, Kim MS, Kälsch J, Kinner S, Faber KN, Moshage H, Gerken G, Syn WK, Friedman SL, Canbay A, Bechmann LP. Anti-TNFα treatment in Crohn's disease: Impact on hepatic steatosis, gut-derived hormones and metabolic status. Liver Int 2021. [PMID: 34219348 DOI: 10.1111/liv.15003] [Reference Citation Analysis]
262 Yang M, Dai J, Jia Y, Suo L, Li S, Guo Y, Liu H, Li L, Yang G. Overexpression of juxtaposed with another zinc finger gene 1 reduces proinflammatory cytokine release via inhibition of stress-activated protein kinases and nuclear factor-κB. FEBS J 2014;281:3193-205. [PMID: 24854865 DOI: 10.1111/febs.12853] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
263 Zhan YT, An W. Roles of liver innate immune cells in nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16(37): 4652-4660 [PMID: 20872965 DOI: 10.3748/wjg.v16.i37.4652] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 62] [Article Influence: 4.9] [Reference Citation Analysis]
264 Susutlertpanya W, Werawatganon D, Siriviriyakul P, Klaikeaw N. Genistein Attenuates Nonalcoholic Steatohepatitis and Increases Hepatic PPARγ in a Rat Model. Evid Based Complement Alternat Med. 2015;2015:509057. [PMID: 26246839 DOI: 10.1155/2015/509057] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
265 Hsieh PS. Inflammatory change of fatty liver induced by intraportal low-dose lipopolysaccharide infusion deteriorates pancreatic insulin secretion in fructose-induced insulin-resistant rats. Liver Int. 2008;28:1167-1175. [PMID: 18397237 DOI: 10.1111/j.1478-3231.2008.01714.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
266 Kirsch R, Clarkson V, Verdonk RC, Marais AD, Shephard EG, Ryffel B, De La M Hall P. Rodent nutritional model of steatohepatitis: Effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency. Journal of Gastroenterology and Hepatology 2006;21:174-82. [DOI: 10.1111/j.1440-1746.2005.04220.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.1] [Reference Citation Analysis]
267 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(7): 1712-1723 [PMID: 24587650 DOI: 10.3748/wjg.v20.i7.1712] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 73] [Article Influence: 9.8] [Reference Citation Analysis]
268 Kaser S, Ebenbichler CF, Tilg H. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease: Treatment of NAFLD. International Journal of Clinical Practice 2010;64:968-83. [DOI: 10.1111/j.1742-1241.2009.02327.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
269 Gyamfi MA, Tanaka Y, He L, Klaassen CD, Wan YJ. Hepatic effects of a methionine-choline-deficient diet in hepatocyte RXRalpha-null mice. Toxicol Appl Pharmacol 2009;234:166-78. [PMID: 18952117 DOI: 10.1016/j.taap.2008.09.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
270 Nigam P, Bhatt SP, Misra A, Vaidya M, Dasgupta J, Chadha DS. Non-alcoholic fatty liver disease is closely associated with sub-clinical inflammation: a case-control study on Asian Indians in North India. PLoS One. 2013;8:e49286. [PMID: 23326306 DOI: 10.1371/journal.pone.0049286] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
271 Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol. 2014;7:221-239. [PMID: 25045276 DOI: 10.2147/ceg.s62831] [Cited by in Crossref: 53] [Cited by in F6Publishing: 114] [Article Influence: 6.6] [Reference Citation Analysis]
272 Ma X, Sun B, Zhu F. Molecular cloning of Kuruma shrimp Marsupenaeus japonicus endonuclease-reverse transcriptase and its positive role in white spot syndrome virus and Vibrio alginolyticus infection. Fish & Shellfish Immunology 2018;73:297-308. [DOI: 10.1016/j.fsi.2017.12.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
273 Horas H Nababan S, Nishiumi S, Kawano Y, Kobayashi T, Yoshida M, Azuma T. Adrenic acid as an inflammation enhancer in non-alcoholic fatty liver disease. Archives of Biochemistry and Biophysics 2017;623-624:64-75. [DOI: 10.1016/j.abb.2017.04.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
274 Sid V, Shang Y, Siow YL, Hewage SM, House JD, O K. Folic Acid Supplementation Attenuates Chronic Hepatic Inflammation in High-Fat Diet Fed Mice. Lipids. 2018;53:709-716. [PMID: 30252139 DOI: 10.1002/lipd.12084] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
275 Rinaldi L, Pafundi PC, Galiero R, Caturano A, Morone MV, Silvestri C, Giordano M, Salvatore T, Sasso FC. Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review. Antioxidants (Basel) 2021;10:270. [PMID: 33578702 DOI: 10.3390/antiox10020270] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
276 Miele L, Vallone S, Cefalo C, La Torre G, Di Stasi C, Vecchio FM, D’Agostino M, Gabrieli ML, Vero V, Biolato M. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:778-786. [PMID: 19664838 DOI: 10.1016/j.jhep.2009.06.008] [Cited by in Crossref: 128] [Cited by in F6Publishing: 112] [Article Influence: 9.8] [Reference Citation Analysis]
277 Sharma BC, Kumar A, Garg V, Reddy RS, Sakhuja P, Sarin SK. A Randomized Controlled Trial Comparing Efficacy of Pentoxifylline and Pioglitazone on Metabolic Factors and Liver Histology in Patients with Non-alcoholic Steatohepatitis. J Clin Exp Hepatol. 2012;2:333-337. [PMID: 25755455 DOI: 10.1016/j.jceh.2012.10.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
278 Ghazarian M, Revelo XS, Nøhr MK, Luck H, Zeng K, Lei H, Tsai S, Schroer SA, Park YJ, Chng MHY, Shen L, D'Angelo JA, Horton P, Chapman WC, Brockmeier D, Woo M, Engleman EG, Adeyi O, Hirano N, Jin T, Gehring AJ, Winer S, Winer DA. Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic Syndrome. Sci Immunol 2017;2:eaai7616. [PMID: 28567448 DOI: 10.1126/sciimmunol.aai7616] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 12.2] [Reference Citation Analysis]
279 den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol. 2004;24:644-649. [PMID: 14715643 DOI: 10.1007/978-1-4614-0650-1_6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 1.7] [Reference Citation Analysis]
280 Shifflet A, Wu GY. Non-alcoholic steatohepatitis: an overview. J Formos Med Assoc. 2009;108:4-12. [PMID: 19181602 DOI: 10.1016/S0929-6646(09)60026-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
281 Sakurai T, Hayasaka T, Sekiguchi H, Satoh H, Chen Z, Chiba H, Hui SP. Dietary salmon milt extracts attenuate hepatosteatosis and liver dysfunction in diet-induced fatty liver model. J Sci Food Agric 2019;99:1675-81. [PMID: 30198086 DOI: 10.1002/jsfa.9352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
282 Shiha G, Soliman R, Mikhail N, Ibrahim A, Serwah A, Khattab M. Changes in hepatic fibrosis stages after achieving SVR following direct‐acting anti‐viral treatment: a prospective study. GastroHep 2020;2:39-48. [DOI: 10.1002/ygh2.384] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
283 Byrne CD. Fatty liver: role of inflammation and fatty acid nutrition. Prostaglandins Leukot Essent Fatty Acids 2010;82:265-71. [PMID: 20189787 DOI: 10.1016/j.plefa.2010.02.012] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 5.7] [Reference Citation Analysis]
284 Marí M, Colell A, Morales A, von Montfort C, Garcia-Ruiz C, Fernández-Checa JC. Redox control of liver function in health and disease. Antioxid Redox Signal. 2010;12:1295-1331. [PMID: 19803748 DOI: 10.1089/ars.2009.2634] [Cited by in Crossref: 114] [Cited by in F6Publishing: 94] [Article Influence: 9.5] [Reference Citation Analysis]
285 Won SM, Park E, Jeong JJ, Ganesan R, Gupta H, Gebru YA, Sharma S, Kim DJ, Suk KT. The Gut Microbiota-Derived Immune Response in Chronic Liver Disease. Int J Mol Sci 2021;22:8309. [PMID: 34361075 DOI: 10.3390/ijms22158309] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
286 Slama L, Le Camus C, Serfaty L, Pialoux G, Capeau J, Gharakhanian S. Metabolic disorders and chronic viral disease: The case of HIV and HCV. Diabetes & Metabolism 2009;35:1-11. [DOI: 10.1016/j.diabet.2008.08.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
287 Gruben N, Aparicio Vergara M, Kloosterhuis NJ, van der Molen H, Stoelwinder S, Youssef S, de Bruin A, Delsing DJ, Kuivenhoven JA, van de Sluis B, Hofker MH, Koonen DP. Chemokine-like receptor 1 deficiency does not affect the development of insulin resistance and nonalcoholic fatty liver disease in mice. PLoS One 2014;9:e96345. [PMID: 24781986 DOI: 10.1371/journal.pone.0096345] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
288 Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. Journal of Hepatology 2004;41:592-8. [DOI: 10.1016/j.jhep.2004.06.030] [Cited by in Crossref: 91] [Cited by in F6Publishing: 93] [Article Influence: 5.1] [Reference Citation Analysis]
289 Takahashi H, Suzuki M, Ikeda H, Kobayashi M, Sase S, Yotsuyanagi H, Maeyama S, Iino S, Itoh F. Evaluation of quantitative portal venous, hepatic arterial, and total hepatic tissue blood flow using xenon CT in alcoholic liver cirrhosis-comparison with liver cirrhosis related to hepatitis C virus and nonalcoholic steatohepatitis. Alcohol Clin Exp Res. 2010;34 Suppl 1:S7-S13. [PMID: 18986379 DOI: 10.1111/j.1530-0277.2008.00755.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
290 Hirsova P, Ibrahim SH, Gores GJ, Malhi H. Lipotoxic lethal and sublethal stress signaling in hepatocytes: Relevance to NASH pathogenesis. J Lipid Res. 2016;57:1758-1770. [PMID: 27049024 DOI: 10.1194/jlr.r066357] [Cited by in Crossref: 112] [Cited by in F6Publishing: 72] [Article Influence: 18.7] [Reference Citation Analysis]
291 Gentile CL, Frye MA, Pagliassotti MJ. Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease. Biofactors 2011;37:8-16. [PMID: 21328622 DOI: 10.1002/biof.135] [Cited by in Crossref: 97] [Cited by in F6Publishing: 64] [Article Influence: 8.1] [Reference Citation Analysis]
292 Marí M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez-Checa JC, García-Ruiz C. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab. 2006;4:185-198. [PMID: 16950136 DOI: 10.1016/j.cmet.2006.07.006] [Cited by in Crossref: 430] [Cited by in F6Publishing: 412] [Article Influence: 26.9] [Reference Citation Analysis]
293 Yan E, Durazo F, Tong M, Hong K. Nonalcoholic Fatty Liver Disease: Pathogenesis, Identification, Progression, and Management. Nutrition Reviews 2007;65:376-84. [DOI: 10.1111/j.1753-4887.2007.tb00315.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
294 Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol. 2014;5:177. [PMID: 24795720 DOI: 10.3389/fimmu.2014. 00177] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
295 Pérez-Martínez L, Pérez-Matute P, Aguilera-Lizarraga J, Rubio-Mediavilla S, Narro J, Recio E, Ochoa-Callejero L, Oteo JA, Blanco JR. Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). J Antimicrob Chemother. 2014;69:1903-1910. [PMID: 24651825 DOI: 10.1093/jac/dku071] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
296 Alfire ME, Treem WR. Nonalcoholic fatty liver disease. Pediatr Ann 2006;35:290-4, 297-9. [PMID: 16637558 DOI: 10.3928/0090-4481-20060401-14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
297 Huang W, Wang G, Xia Y, Xiong Z, Ai L. Bile salt hydrolase-overexpressing Lactobacillus strains can improve hepatic lipid accumulation in vitro in an NAFLD cell model. Food Nutr Res 2020;64. [PMID: 33281535 DOI: 10.29219/fnr.v64.3751] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
298 Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis. 2007;11:75-104, ix. [PMID: 17544973 DOI: 10.1016/j.cld.2007.02.011] [Cited by in Crossref: 104] [Cited by in F6Publishing: 100] [Article Influence: 6.9] [Reference Citation Analysis]
299 Kuchay MS, Choudhary NS, Mishra SK. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr 2020;14:1875-87. [PMID: 32998095 DOI: 10.1016/j.dsx.2020.09.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
300 Akhigbe R, Ajayi A. The impact of reactive oxygen species in the development of cardiometabolic disorders: a review. Lipids Health Dis 2021;20:23. [PMID: 33639960 DOI: 10.1186/s12944-021-01435-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
301 Zhang X, Li Z, Liu D, Xu X, Shen W, Mei Z. Effects of probucol on hepatic tumor necrosis factor-α, interleukin-6 and adiponectin receptor-2 expression in diabetic rats. Journal of Gastroenterology and Hepatology 2009;24:1058-63. [DOI: 10.1111/j.1440-1746.2008.05719.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
302 Maina V, Sutti S, Locatelli I, Vidali M, Mombello C, Bozzola C, Albano E. Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. Clin Sci (Lond). 2012;122:545-553. [PMID: 22142284 DOI: 10.1042/cs20110366] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
303 Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, Szabo G. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology. 2009;49:989-997. [PMID: 19115316 DOI: 10.1002/hep.22711] [Cited by in Crossref: 164] [Cited by in F6Publishing: 157] [Article Influence: 12.6] [Reference Citation Analysis]
304 Das UN. Nonalcoholic fatty liver disease as a pro-resolution defective disorder. Nutrition 2013;29:345-9. [PMID: 22858195 DOI: 10.1016/j.nut.2012.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
305 Das UN. A defect in the activities of Δ6 and Δ5 desaturases and pro-resolution bioactive lipids in the pathobiology of non-alcoholic fatty liver disease. World J Diabetes 2011; 2(11): 176-188 [PMID: 22087354 DOI: 10.4239/wjd.v2.i11.176] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
306 García-Compeán D, González-González JA, Lavalle-González FJ, González-Moreno EI, Maldonado-Garza HJ, Villarreal-Pérez JZ. The treatment of diabetes mellitus of patients with chronic liver disease. Ann Hepatol. 2015;14:780-788. [PMID: 26436350 DOI: 10.5604/16652681.1171746] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
307 Sanyal AJ. Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:46-53. [PMID: 16265100 DOI: 10.1038/ncpgasthep0084] [Cited by in Crossref: 147] [Cited by in F6Publishing: 146] [Article Influence: 8.6] [Reference Citation Analysis]
308 Toshimitsu K, Matsuura B, Ohkubo I, Niiya T, Furukawa S, Hiasa Y, Kawamura M, Ebihara K, Onji M. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition. 2007;23:46-52. [PMID: 17140767 DOI: 10.1016/j.nut.2006.09.004] [Cited by in Crossref: 165] [Cited by in F6Publishing: 150] [Article Influence: 10.3] [Reference Citation Analysis]
309 Choi W, Namkung J, Hwang I, Kim H, Lim A, Park HJ, Lee HW, Han KH, Park S, Jeong JS, Bang G, Kim YH, Yadav VK, Karsenty G, Ju YS, Choi C, Suh JM, Park JY. Serotonin signals through a gut-liver axis to regulate hepatic steatosis. Nat Commun. 2018;9:4824. [PMID: 30446669 DOI: 10.1038/s41467-018-07287-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
310 Pérez-Aguilar F. [Etiopathogenesis of non-alcoholic steatohepatitis]. Gastroenterol Hepatol 2005;28:396-406. [PMID: 16137475 DOI: 10.1157/13077761] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
311 Caballero F, Fernández A, Matías N, Martínez L, Fucho R, Elena M, Caballeria J, Morales A, Fernández-Checa JC, García-Ruiz C. Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione. J Biol Chem 2010;285:18528-36. [PMID: 20395294 DOI: 10.1074/jbc.M109.099333] [Cited by in Crossref: 142] [Cited by in F6Publishing: 87] [Article Influence: 11.8] [Reference Citation Analysis]
312 Manco M, Marcellini M, Giannone G, Nobili V. Correlation of Serum TNF-α Levels and Histologic Liver Injury Scores in Pediatric Nonalcoholic Fatty Liver Disease. Am J Clin Pathol 2007;127:954-60. [DOI: 10.1309/6vj4dwgydu0xyj8q] [Cited by in Crossref: 128] [Cited by in F6Publishing: 67] [Article Influence: 8.5] [Reference Citation Analysis]
313 Yalniz M, Bahcecioglu IH, Ataseven H, Ustundag B, Ilhan F, Poyrazoglu OK, Erensoy A. Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediators Inflamm. 2006;2006:34295. [PMID: 17392582 DOI: 10.1155/mi/2006/34295] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
314 Lim E, Lim JY, Kim E, Kim YS, Shin JH, Seok PR, Jung S, Yoo SH, Kim Y. Xylobiose, an Alternative Sweetener, Ameliorates Diabetes-Related Metabolic Changes by Regulating Hepatic Lipogenesis and miR-122a/33a in db/db Mice. Nutrients 2016;8:E791. [PMID: 27929393 DOI: 10.3390/nu8120791] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
315 Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013;10:627-636. [PMID: 23958599 DOI: 10.1038/nrgastro.2013.149] [Cited by in Crossref: 335] [Cited by in F6Publishing: 320] [Article Influence: 37.2] [Reference Citation Analysis]
316 Chiu WC, Yang HH, Chiang SC, Chou YX, Yang HT. Auricularia polytricha aqueous extract supplementation decreases hepatic lipid accumulation and improves antioxidative status in animal model of nonalcoholic fatty liver. Biomedicine (Taipei) 2014;4:12. [PMID: 25520925 DOI: 10.7603/s40681-014-0012-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
317 Jensen VS, Hvid H, Damgaard J, Nygaard H, Ingvorsen C, Wulff EM, Lykkesfeldt J, Fledelius C. Dietary fat stimulates development of NAFLD more potently than dietary fructose in Sprague-Dawley rats. Diabetol Metab Syndr. 2018;10:4. [PMID: 29410708 DOI: 10.1186/s13098-018-0307-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
318 Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM. Model of nonalcoholic steatohepatitis. Am J Clin Nutr 2004;79:502-9. [PMID: 14985228 DOI: 10.1093/ajcn/79.3.502] [Cited by in Crossref: 286] [Cited by in F6Publishing: 282] [Article Influence: 15.9] [Reference Citation Analysis]
319 Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med. 2009;41:265-278. [PMID: 19353360 DOI: 10.1080/07853890802552437] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 5.9] [Reference Citation Analysis]
320 Lana JP, Martins LB, Oliveira MC, Menezes-Garcia Z, Yamada LT, Vieira LQ, Teixeira MM, Ferreira AV. TNF and IL-18 cytokines may regulate liver fat storage under homeostasis conditions. Appl Physiol Nutr Metab 2016;41:1295-302. [PMID: 27863204 DOI: 10.1139/apnm-2016-0265] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
321 Levene AP, Goldin RD. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology. 2012;61:141-152. [PMID: 22372457 DOI: 10.1111/j.1365-2559.2011.04145.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 108] [Article Influence: 11.4] [Reference Citation Analysis]
322 Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: An update. World J Gastroenterol 2008; 14(2): 185-192 [PMID: 18186553 DOI: 10.3748/wjg.14.185] [Cited by in CrossRef: 198] [Cited by in F6Publishing: 193] [Article Influence: 14.1] [Reference Citation Analysis]
323 Cortez-pinto H, de Moura MC, Day CP. Non-alcoholic steatohepatitis: From cell biology to clinical practice. Journal of Hepatology 2006;44:197-208. [DOI: 10.1016/j.jhep.2005.09.002] [Cited by in Crossref: 139] [Cited by in F6Publishing: 129] [Article Influence: 8.7] [Reference Citation Analysis]
324 Thagia I, Shaw EJ, Smith E, Else KJ, Rigby RJ. Intestinal epithelial suppressor of cytokine signaling 3 enhances microbial-induced inflammatory tumor necrosis factor-α, contributing to epithelial barrier dysfunction. Am J Physiol Gastrointest Liver Physiol 2015;308:G25-31. [PMID: 25377316 DOI: 10.1152/ajpgi.00214.2014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
325 Iliopoulos D, Drosatos K, Hiyama Y, Goldberg IJ, Zannis VI. MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. J Lipid Res 2010;51:1513-23. [PMID: 20124555 DOI: 10.1194/jlr.M004812] [Cited by in Crossref: 212] [Cited by in F6Publishing: 110] [Article Influence: 17.7] [Reference Citation Analysis]
326 Ratziu V, Vispo M, Tahiri M, Bonyhay L, de Torres M, Bernhardt C, Poynard T, Lebray P. Peut-on traiter la stéatohépatite métabolique ? Gastroentérologie Clinique et Biologique 2007;31:333-40. [DOI: 10.1016/s0399-8320(07)89386-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
327 de Freitas Carvalho MM, Lage NN, de Souza Paulino AH, Pereira RR, de Almeida LT, da Silva TF, de Brito Magalhães CL, de Lima WG, Silva ME, Pedrosa ML, da Costa Guerra JF. Effects of açai on oxidative stress, ER stress, and inflammation-related parameters in mice with high fat diet-fed induced NAFLD. Sci Rep 2019;9:8107. [PMID: 31147590 DOI: 10.1038/s41598-019-44563-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
328 Yoneda M, Uchiyama T, Kato S, Endo H, Fujita K, Yoneda K, Mawatari H, Iida H, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Kobayashi N, Kubota K, Saito S, Maeyama S, Sagara M, Aburatani H, Kodama T, Nakajima A. Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC Gastroenterol 2008;8:53. [PMID: 19014569 DOI: 10.1186/1471-230X-8-53] [Cited by in Crossref: 54] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
329 Hong M, Jung J, Park HS, Lee SM, Jeong NJ, Kim SH, Lee KW, Lee JA, Kim MS. Shaofu Zhuyu decoction ameliorates obesity-mediated hepatic steatosis and systemic inflammation by regulating metabolic pathways. PLoS One 2017;12:e0178514. [PMID: 28570676 DOI: 10.1371/journal.pone.0178514] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
330 Amini R, Yazdanparast R, Aghazadeh S, Ghaffari SH. Teucrium polium reversed the MCD diet-induced liver injury in rats. Hum Exp Toxicol 2011;30:1303-12. [PMID: 21056947 DOI: 10.1177/0960327110388961] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
331 Ahmed MH, Byrne CD. Non-Alcoholic Fatty Liver Disease. In: Byrne CD, Wild SH, editors. The Metabolic Syndrome. Oxford: Wiley-Blackwell; 2011. pp. 245-77. [DOI: 10.1002/9781444347319.ch15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
332 Fusco A, Miele L, D'Uonnolo A, Forgione A, Riccardi L, Cefalo C, Barini A, Bianchi A, Giampietro A, Cimino V, Landolfi R, Grieco A, De Marinis L. Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels. Clin Endocrinol (Oxf). 2012;77:531-536. [PMID: 22077984 DOI: 10.1111/j.1365-2265.2011.04291.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
333 Zhang H, He Y, Chung PK, Tong TK, Fu FH, Chen Y, Jiao G. Effects of 12 Weeks of Exercise on Hepatic TNF-α and PPARα in an Animal Model of High-Fat Diet-Induced Nonalcoholic Steatohepatitis. Journal of Exercise Science & Fitness 2009;7:18-23. [DOI: 10.1016/s1728-869x(09)60003-4] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
334 Oh S, Oshida N, Someya N, Maruyama T, Isobe T, Okamoto Y, Kim T, Kim B, Shoda J. Whole-body vibration for patients with nonalcoholic fatty liver disease: a 6-month prospective study. Physiol Rep 2019;7:e14062. [PMID: 31087530 DOI: 10.14814/phy2.14062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
335 Alkhouri N, Carter-Kent C, Feldstein AE. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol 2011;5:201-12. [PMID: 21476915 DOI: 10.1586/egh.11.6] [Cited by in Crossref: 134] [Cited by in F6Publishing: 134] [Article Influence: 12.2] [Reference Citation Analysis]
336 Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048-1058. [PMID: 15625647 DOI: 10.1016/s1542-3565(04)00440-9] [Cited by in Crossref: 255] [Cited by in F6Publishing: 113] [Article Influence: 15.0] [Reference Citation Analysis]
337 Sun B, Qian X, Zhu F. Molecular characterization of shrimp harbinger transposase derived 1 (HARBI1)-like and its role in white spot syndrome virus and Vibrio alginolyticus infection. Fish & Shellfish Immunology 2018;78:222-32. [DOI: 10.1016/j.fsi.2018.04.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
338 Luther J, Garber JJ, Khalili H, Dave M, Bale SS, Jindal R, Motola DL, Luther S, Bohr S, Jeoung SW, Deshpande V, Singh G, Turner JR, Yarmush ML, Chung RT, Patel SJ. Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability. Cell Mol Gastroenterol Hepatol 2015;1:222-32. [PMID: 26405687 DOI: 10.1016/j.jcmgh.2015.01.001] [Cited by in Crossref: 119] [Cited by in F6Publishing: 106] [Article Influence: 17.0] [Reference Citation Analysis]
339 Schwenger KJP, Bolzon CM, Li C, Allard JP. Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria. Eur J Nutr 2019;58:1771-84. [PMID: 30306296 DOI: 10.1007/s00394-018-1844-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
340 Anderson N, Borlak J. Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis. Pharmacol Rev 2008;60:311-57. [DOI: 10.1124/pr.108.00001] [Cited by in Crossref: 260] [Cited by in F6Publishing: 249] [Article Influence: 18.6] [Reference Citation Analysis]
341 Charlton M. Fetal obesity syndrome: maternal nutrition as a cause of nonalcoholic steatohepatitis. Hepatology 2009;50:1696-8. [PMID: 19937683 DOI: 10.1002/hep.23371] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
342 Saeed NM, Mansour AM, Allam S. Lycopene induces insulin signaling and alleviates fibrosis in experimental model of non-alcoholic fatty liver disease in rats. PharmaNutrition 2020;14:100225. [DOI: 10.1016/j.phanu.2020.100225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
343 Byun JS, Yi HS. Hepatic Immune Microenvironment in Alcoholic and Nonalcoholic Liver Disease. Biomed Res Int. 2017;2017:6862439. [PMID: 28852648 DOI: 10.1155/2017/6862439] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
344 El-Tanbouly DM, Abdelsalam RM, Attia AS, Abdel-Aziz MT. Pretreatment with magnesium ameliorates lipopolysaccharide-induced liver injury in mice. Pharmacol Rep 2015;67:914-20. [PMID: 26398385 DOI: 10.1016/j.pharep.2015.02.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
345 Savari F, Mard SA, Badavi M, Rezaie A, Gharib-Naseri MK. A new method to induce nonalcoholic steatohepatitis (NASH) in mice. BMC Gastroenterol 2019;19:125. [PMID: 31307427 DOI: 10.1186/s12876-019-1041-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
346 Li M, Reynolds CM, Sloboda DM, Gray C, Vickers MH. Effects of taurine supplementation on hepatic markers of inflammation and lipid metabolism in mothers and offspring in the setting of maternal obesity. PLoS One 2013;8:e76961. [PMID: 24146946 DOI: 10.1371/journal.pone.0076961] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
347 Mcavoy NC, Ferguson JW, Campbell IW, Hayes PC. Review: Non-alcoholic fatty liver disease: natural history, pathogenesis and treatment. Diabetes & Vascular Disease 2006;6:251-60. [DOI: 10.1177/14746514060060060201] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
348 Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-? or adiponectin? Hepatology 2004;40:46-54. [DOI: 10.1002/hep.20280] [Cited by in Crossref: 638] [Cited by in F6Publishing: 631] [Article Influence: 35.4] [Reference Citation Analysis]
349 Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A, Gugenheim J, Barr J, Mato JM, Le Marchand-Brustel Y, Tran A, Gual P. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One 2010;5:e13577. [PMID: 21042596 DOI: 10.1371/journal.pone.0013577] [Cited by in Crossref: 137] [Cited by in F6Publishing: 145] [Article Influence: 11.4] [Reference Citation Analysis]
350 Vansaun MN, Mendonsa AM, Lee Gorden D. Hepatocellular proliferation correlates with inflammatory cell and cytokine changes in a murine model of nonalchoholic fatty liver disease. PLoS One. 2013;8:e73054. [PMID: 24039859 DOI: 10.1371/journal.pone.0073054] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
351 Canup BS, Song H, Le Ngo V, Meng X, Denning TL, Garg P, Laroui H. CD98 siRNA-loaded nanoparticles decrease hepatic steatosis in mice. Dig Liver Dis 2017;49:188-96. [PMID: 27939923 DOI: 10.1016/j.dld.2016.11.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
352 Rafiei H, Omidian K, Bandy B. Comparison of dietary polyphenols for protection against molecular mechanisms underlying nonalcoholic fatty liver disease in a cell model of steatosis. Mol Nutr Food Res 2017;61:1600781. [DOI: 10.1002/mnfr.201600781] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
353 Ribeiro PS, Cortez-Pinto H, Solá S, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME, Rodrigues CM. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol. 2004;99:1708-1717. [PMID: 15330907 DOI: 10.1111/j.1572-0241.2004.40009.x] [Cited by in Crossref: 255] [Cited by in F6Publishing: 262] [Article Influence: 14.2] [Reference Citation Analysis]
354 Day CP. From fat to inflammation. Gastroenterology. 2006;130:207-210. [PMID: 16401483 DOI: 10.1053/j.gastro.2005.11.017] [Cited by in Crossref: 269] [Cited by in F6Publishing: 268] [Article Influence: 16.8] [Reference Citation Analysis]
355 Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, Cioffi M, Ruggiero G, Adinolfi LE. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther. 2006;24:1349-1357. [PMID: 17059516 DOI: 10.1111/j.1365-2036.2006.03114.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 5.1] [Reference Citation Analysis]
356 Sans A, Bonnafous S, Rousseau D, Patouraux S, Canivet CM, Leclere PS, Tran-Van-Nhieu J, Luci C, Bailly-Maitre B, Xu X, Lee AH, Minehira K, Anty R, Tran A, Iannelli A, Gual P. The Differential Expression of Cide Family Members is Associated with Nafld Progression from Steatosis to Steatohepatitis. Sci Rep 2019;9:7501. [PMID: 31097771 DOI: 10.1038/s41598-019-43928-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
357 Seo YS, Kim JH, Jo NY, Choi KM, Baik SH, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH, Kim A, Yeon JE. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol 2008;23:102-9. [PMID: 18171348 DOI: 10.1111/j.1440-1746.2006.04819.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 46] [Article Influence: 0.8] [Reference Citation Analysis]
358 Feltenberger JD, Andrade JM, Paraíso A, Barros LO, Filho AB, Sinisterra RD, Sousa FB, Guimarães AL, de Paula AM, Campagnole-Santos MJ, Qureshi M, dos Santos RA, Santos SH. Oral formulation of angiotensin-(1-7) improves lipid metabolism and prevents high-fat diet-induced hepatic steatosis and inflammation in mice. Hypertension 2013;62:324-30. [PMID: 23753417 DOI: 10.1161/HYPERTENSIONAHA.111.00919] [Cited by in Crossref: 68] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
359 Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(39): 14205-14218 [PMID: 25339807 DOI: 10.3748/wjg.v20.i39.14205] [Cited by in CrossRef: 198] [Cited by in F6Publishing: 184] [Article Influence: 24.8] [Reference Citation Analysis]
360 Moschen AR, Kaser S, Tilg H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab. 2013;24:537-545. [PMID: 23827477 DOI: 10.1016/j.tem.2013.05.009] [Cited by in Crossref: 106] [Cited by in F6Publishing: 101] [Article Influence: 11.8] [Reference Citation Analysis]
361 Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 2005;54:117-121. [PMID: 15591515 DOI: 10.1136/gut.2003.037010] [Cited by in Crossref: 301] [Cited by in F6Publishing: 285] [Article Influence: 17.7] [Reference Citation Analysis]
362 Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol. 2008;43:509-518. [PMID: 18648737 DOI: 10.1007/s00535-008-2193-6] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 8.5] [Reference Citation Analysis]
363 Yue S, Wang T, Yang Y, Fan Y, Zhou L, Li M, Fu F. Lipopolysaccharide/D-galactosamine-induced acute liver injury could be attenuated by dopamine receptor agonist rotigotine via regulating NF-κB signaling pathway. Int Immunopharmacol 2021;96:107798. [PMID: 34162160 DOI: 10.1016/j.intimp.2021.107798] [Reference Citation Analysis]
364 Schattenberg JM, Czaja MJ. TNF/TNF Receptors. In: Dufour J, Clavien P, editors. Signaling Pathways in Liver Diseases. Berlin: Springer Berlin Heidelberg; 2010. pp. 161-77. [DOI: 10.1007/978-3-642-00150-5_10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
365 Qian XW, Fan ZP, Wang XH, Sheng L, Xi ZF, Qiu DK. Expression of adiponectin and its receptor 2 during the development of nonalcoholic steatohepatitis. Shijie Huaren Xiaohua Zazhi 2009; 17(19): 1925-1930 [DOI: 10.11569/wcjd.v17.i19.1925] [Reference Citation Analysis]
366 Hassan K, Bhalla V, Regal MEE, A-Kader HH. Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. World J Gastroenterol 2014; 20(34): 12082-12101 [PMID: 25232245 DOI: 10.3748/wjg.v20.i34.12082] [Cited by in CrossRef: 110] [Cited by in F6Publishing: 95] [Article Influence: 13.8] [Reference Citation Analysis]
367 Liu YZ, Chen JK, Zhang Y, Wang X, Qu S, Jiang CL. Chronic stress induces steatohepatitis while decreases visceral fat mass in mice. BMC Gastroenterol 2014;14:106. [PMID: 24916323 DOI: 10.1186/1471-230X-14-106] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
368 Budick-Harmelin N, Dudas J, Demuth J, Madar Z, Ramadori G, Tirosh O. Triglycerides potentiate the inflammatory response in rat Kupffer cells. Antioxid Redox Signal. 2008;10:2009-2022. [PMID: 18710323 DOI: 10.1089/ars.2007.1876] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
369 Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? J Hepatol. 2006;44:253-261. [PMID: 16364488 DOI: 10.1016/j.jhep.2005.11.030] [Cited by in Crossref: 102] [Cited by in F6Publishing: 92] [Article Influence: 6.0] [Reference Citation Analysis]
370 Chen M, Xing J, Pan D, Peng X, Gao P. Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF-κB pathway. Biomed Pharmacother 2020;128:110286. [PMID: 32521450 DOI: 10.1016/j.biopha.2020.110286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
371 Bieghs V, Rensen PC, Hofker MH, Shiri-sverdlov R. NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages. Atherosclerosis 2012;220:287-93. [DOI: 10.1016/j.atherosclerosis.2011.08.041] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
372 Maheshwari A, Thuluvath PJ. Endocrine diseases and the liver. Clin Liver Dis 2011;15:55-67. [PMID: 21111993 DOI: 10.1016/j.cld.2010.09.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
373 Hong XZ, Li LD, Wu LM. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol. 2007;34:27-35. [PMID: 17201732 DOI: 10.1111/j.1440-1681.2007.04547.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
374 Malpique R, Bassols J, López-bermejo A, Diaz M, Villarroya F, Pavia J, Congo A, de Zegher F, Ibáñez L. Liver volume and hepatic adiposity in childhood: relations to body growth and visceral fat. Int J Obes 2018;42:65-71. [DOI: 10.1038/ijo.2017.198] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
375 Fukushima J, Kamada Y, Matsumoto H, Yoshida Y, Ezaki H, Takemura T, Saji Y, Igura T, Tsutsui S, Kihara S, Funahashi T, Shimomura I, Tamura S, Kiso S, Hayashi N. Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization. Hepatol Res. 2009;39:724-738. [PMID: 19473437 DOI: 10.1111/j.1872-034x.2009.00509.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
376 Cheng Q, Li N, Chen M, Zheng J, Qian Z, Wang X, Huang C, Xu S, Shi G. Cyclooxygenase-2 promotes hepatocellular apoptosis by interacting with TNF-α and IL-6 in the pathogenesis of nonalcoholic steatohepatitis in rats. Dig Dis Sci 2013;58:2895-902. [PMID: 23975340 DOI: 10.1007/s10620-013-2823-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
377 Baranova A, Younossi ZM. Adipokines in Non-Alcoholic Fatty Liver Disease. In: Fantuzzi G, Mazzone T, editors. Adipose Tissue and Adipokines in Health and Disease. Totowa: Humana Press; 2007. pp. 291-305. [DOI: 10.1007/978-1-59745-370-7_22] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
378 Fu L, Wu Z, Chu Y, Chen W, Gao L, Mu S, Zhao J, Zhao E. Explore the Mechanism of Astragalus mongholicus Bunge against Nonalcoholic Fatty Liver Disease Based on Network Pharmacology and Experimental Verification. Gastroenterology Research and Practice 2022;2022:1-17. [DOI: 10.1155/2022/4745042] [Reference Citation Analysis]
379 Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol 2016;311:G1018-36. [PMID: 27686615 DOI: 10.1152/ajpgi.00245.2016] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 7.7] [Reference Citation Analysis]
380 Kirk EP, Klein S. Pathogenesis and pathophysiology of the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2009;11:761-5. [PMID: 20021538 DOI: 10.1111/j.1559-4572.2009.00054.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 4.8] [Reference Citation Analysis]
381 Choi KM. Non-alcoholic Fatty Liver Disease and Adiponectin. Korean Diabetes J 2008;32:98. [DOI: 10.4093/kdj.2008.32.2.98] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
382 Holterman AX, Guzman G, Fantuzzi G, Wang H, Aigner K, Browne A, Holterman M. Nonalcoholic fatty liver disease in severely obese adolescent and adult patients. Obesity (Silver Spring). 2013;21:591-597. [PMID: 23592668 DOI: 10.1002/oby.20174] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
383 Lee SJ, Heinrich G, Fedorova L, Al-Share QY, Ledford KJ, Fernstrom MA, McInerney MF, Erickson SK, Gatto-Weis C, Najjar SM. Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule 1 mutant mice. Gastroenterology 2008;135:2084-95. [PMID: 18848945 DOI: 10.1053/j.gastro.2008.08.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
384 Raff EJ, Kakati D, Bloomer JR, Shoreibah M, Rasheed K, Singal AK. Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases. J Clin Transl Hepatol. 2015;3:9-16. [PMID: 26356325 DOI: 10.14218/jcth.2015.00001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
385 Liu L, Hu Q, Wu H, Wang X, Gao C, Chen G, Yao P, Gong Z. Dietary DHA/EPA Ratio Changes Fatty Acid Composition and Attenuates Diet-Induced Accumulation of Lipid in the Liver of ApoE-/- Mice. Oxid Med Cell Longev 2018;2018:6256802. [PMID: 30538803 DOI: 10.1155/2018/6256802] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
386 Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev. 2004;5:27-42. [PMID: 14969505 DOI: 10.1111/j.1467-789x.2004.00126.x] [Cited by in Crossref: 186] [Cited by in F6Publishing: 66] [Article Influence: 10.3] [Reference Citation Analysis]
387 Kanmani P, Ansari A, Villena J, Kim H. Immunobiotics Beneficially Modulate TLR4 Signaling Triggered by Lipopolysaccharide and Reduce Hepatic Steatosis In Vitro. J Immunol Res 2019;2019:3876896. [PMID: 31001563 DOI: 10.1155/2019/3876896] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
388 Mariqueo TA, Zúñiga-Hernández J. Omega-3 derivatives, specialized pro-resolving mediators: Promising therapeutic tools for the treatment of pain in chronic liver disease. Prostaglandins Leukot Essent Fatty Acids 2020;158:102095. [PMID: 32450460 DOI: 10.1016/j.plefa.2020.102095] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
389 Olleros ML, Vesin D, Fotio AL, Santiago-Raber ML, Tauzin S, Szymkowski DE, Garcia I. Soluble TNF, but not membrane TNF, is critical in LPS-induced hepatitis. J Hepatol 2010;53:1059-68. [PMID: 20813418 DOI: 10.1016/j.jhep.2010.05.029] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
390 Abdou RM, Zhu L, Baker RD, Baker SS. Gut Microbiota of Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1268-1281. [PMID: 26898658 DOI: 10.1007/s10620-016-4045-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
391 Jiang J, Torok N. Nonalcoholic steatohepatitis and the metabolic syndrome. Metab Syndr Relat Disord. 2008;6:1-7. [PMID: 18370830 DOI: 10.1089/met.2007.0026] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
392 Wang C, Cui Y, Li C, Zhang Y, Xu S, Li X, Li H, Zhang X. Nrf2 deletion causes “benign” simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet. Lipids Health Dis. 2013;12:165. [PMID: 24188280 DOI: 10.1186/1476-511x-12-165] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
393 Mcclain CJ, Mokshagundam SPL, Barve SS, Song Z, Hill DB, Chen T, Deaciuc I. Mechanisms of non-alcoholic steatohepatitis. Alcohol 2004;34:67-79. [DOI: 10.1016/j.alcohol.2004.07.007] [Cited by in Crossref: 72] [Cited by in F6Publishing: 78] [Article Influence: 4.0] [Reference Citation Analysis]
394 Hui JM, Farrell GC. Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them. Journal of Gastroenterology and Hepatology 2003;18:1115-7. [DOI: 10.1046/j.1440-1746.2003.03170.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
395 Takeshita Y, Takamura T, Ando H, Hamaguchi E, Takazakura A, Matsuzawa-nagata N, Kaneko S. Cross talk of tumor necrosis factor-α and the renin–angiotensin system in tumor necrosis factor-α-induced plasminogen activator inhibitor-1 production from hepatocytes. European Journal of Pharmacology 2008;579:426-32. [DOI: 10.1016/j.ejphar.2007.11.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
396 Hsieh PS, Hsieh YJ. Impact of liver diseases on the development of type 2 diabetes mellitus. World J Gastroenterol 2011; 17(48): 5240-5245 [PMID: 22219592 DOI: 10.3748/wjg.v17.i48.5240] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
397 Shimizu A, Takamura T, Matsuzawa N, Nakamura S, Nabemoto S, Takeshita Y, Misu H, Kurita S, Sakurai M, Yokoyama M. Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line. Metabolism. 2007;56:1478-1485. [PMID: 17950097 DOI: 10.1016/j.metabol.2007.06.013] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
398 Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008; 14(2): 193-199 [PMID: 18186554 DOI: 10.3748/wjg.14.193] [Cited by in CrossRef: 214] [Cited by in F6Publishing: 197] [Article Influence: 15.3] [Reference Citation Analysis]
399 Marion AW, Baker AJ, Dhawan A. Fatty liver disease in children. Arch Dis Child 2004;89:648-52. [PMID: 15210498 DOI: 10.1136/adc.2003.029942] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
400 Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. J Biol Chem. 2012;287:40161-40172. [PMID: 23066023 DOI: 10.1074/jbc.m112.417014] [Cited by in Crossref: 253] [Cited by in F6Publishing: 153] [Article Influence: 25.3] [Reference Citation Analysis]
401 Ong JP, Younossi ZM. Approach to the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2005;9:617-34. [DOI: 10.1016/j.cld.2005.07.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
402 Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol. 2002;97:2714-2724. [PMID: 12425538 DOI: 10.1111/j.1572-0241.2002.07069.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 46] [Article Influence: 0.5] [Reference Citation Analysis]
403 Akazawa Y, Nakao K. Lipotoxicity pathways intersect in hepatocytes: Endoplasmic reticulum stress, c-Jun N-terminal kinase-1, and death receptors. Hepatol Res 2016;46:977-84. [PMID: 26938481 DOI: 10.1111/hepr.12658] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
404 Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab. 2008;19:371-379. [PMID: 18929493 DOI: 10.1016/j.tem.2008.08.005] [Cited by in Crossref: 288] [Cited by in F6Publishing: 280] [Article Influence: 20.6] [Reference Citation Analysis]
405 Poniachik J, Csendes A, Díaz JC, Rojas J, Burdiles P, Maluenda F, Smok G, Rodrigo R, Videla LA. Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. Cytokine 2006;33:252-7. [PMID: 16564703 DOI: 10.1016/j.cyto.2006.02.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 2.9] [Reference Citation Analysis]
406 Katsarou A, Moustakas II, Pyrina I, Lembessis P, Koutsilieris M, Chatzigeorgiou A. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(17): 1993-2011 [PMID: 32536770 DOI: 10.3748/wjg.v26.i17.1993] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
407 Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K, Nagaoka S, Matsumoto T, Takii Y, Kusumoto K. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int. 2006;26:39-45. [PMID: 16420507 DOI: 10.1111/j.1478-3231.2005.01191.x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 128] [Article Influence: 7.9] [Reference Citation Analysis]
408 Park SH. [Nonalcoholic steatohepatitis: pathogenesis and treatment]. Korean J Hepatol 2008;14:12-27. [PMID: 18367854 DOI: 10.3350/kjhep.2008.14.1.12] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
409 El-Sherbiny M, Eldosoky M, El-Shafey M, Othman G, Elkattawy HA, Bedir T, Elsherbiny NM. Vitamin D nanoemulsion enhances hepatoprotective effect of conventional vitamin D in rats fed with a high-fat diet. Chem Biol Interact 2018;288:65-75. [PMID: 29653100 DOI: 10.1016/j.cbi.2018.04.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
410 Kim E, Shin J, Seok PR, Kim M, Yoo S, Kim Y. Phyllodulcin, a natural functional sweetener, improves diabetic metabolic changes by regulating hepatic lipogenesis, inflammation, oxidative stress, fibrosis, and gluconeogenesis in db/db mice. Journal of Functional Foods 2018;42:1-11. [DOI: 10.1016/j.jff.2017.12.038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
411 Cimini FA, Barchetta I, Carotti S, Bertoccini L, Baroni MG, Vespasiani-Gentilucci U, Cavallo MG, Morini S. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(19): 3407-3417 [PMID: 28596677 DOI: 10.3748/wjg.v23.i19.3407] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 36] [Article Influence: 8.4] [Reference Citation Analysis]
412 Duvnjak M, Baršić N, Tomašić V, Lerotić I. Genetic polymorphisms in non-alcoholic fatty liver disease: Clues to pathogenesis and disease progression. World J Gastroenterol 2009; 15(48): 6023-6027 [PMID: 20027673 DOI: 10.3748/wjg.15.6023] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
413 Acharya C, Bajaj JS. Gut Microbiota and Complications of Liver Disease. Gastroenterol Clin North Am. 2017;46:155-169. [PMID: 28164848 DOI: 10.1016/j.gtc.2016.09.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
414 Schreuder TC, Verwer BJ, Nieuwkerk CMV, Mulder CJ. Nonalcoholic fatty liver disease: An overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol 2008; 14(16): 2474-2486 [PMID: 18442193 DOI: 10.3748/wjg.14.2474] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 111] [Article Influence: 8.0] [Reference Citation Analysis]
415 Vial P, Riquelme A, Pizarro M, Solís N, Andrés Madariaga J, Aguayo G, Duarte I, Soza A, Accatino L, Arrese M. Pentoxifylline does not prevent neither liver damage nor early profibrogenic events in a rat model of non-alcoholic steatohepatitis. Annals of Hepatology 2006;5:25-9. [DOI: 10.1016/s1665-2681(19)32035-6] [Cited by in Crossref: 8] [Article Influence: 0.5] [Reference Citation Analysis]
416 Koca SS, Bahcecioglu IH, Poyrazoglu OK, Ozercan IH, Sahin K, Ustundag B. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation. 2008;31:91-98. [PMID: 18066656 DOI: 10.1007/s10753-007-9053-z] [Cited by in Crossref: 88] [Cited by in F6Publishing: 95] [Article Influence: 5.9] [Reference Citation Analysis]
417 Tariq Z, Green CJ, Hodson L. Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)? Liver Int 2014;34:e180-90. [DOI: 10.1111/liv.12523] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 8.4] [Reference Citation Analysis]
418 Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of Insulin Resistance in MAFLD. Int J Mol Sci 2021;22:4156. [PMID: 33923817 DOI: 10.3390/ijms22084156] [Reference Citation Analysis]
419 Tilg H, Moschen AR. Relevance of TNF -α gene polymorphisms in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2014;5:155-8. [DOI: 10.1586/egh.11.17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
420 Bloomgarden ZT. Non-Alcoholic Fatty Liver Disease and Malignancy as Complications of Insulin Resistance. Metabolic Syndrome and Related Disorders 2005;3:316-27. [DOI: 10.1089/met.2005.3.316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
421 de Castro Barbosa T, Alm PS, Krook A, Barrès R, Zierath JR. Paternal high-fat diet transgenerationally impacts hepatic immunometabolism. FASEB J 2019;33:6269-80. [PMID: 30768368 DOI: 10.1096/fj.201801879RR] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
422 Wang Y, Zhou M, Lam KS, Xu A. Protective roles of adiponectin in obesity-related fatty liver diseases: mechanisms and therapeutic implications. Arq Bras Endocrinol Metabol 2009;53:201-12. [PMID: 19466213 DOI: 10.1590/s0004-27302009000200012] [Cited by in Crossref: 56] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
423 Li J, Sapper TN, Mah E, Moller MV, Kim JB, Chitchumroonchokchai C, McDonald JD, Bruno RS. Green tea extract treatment reduces NFκB activation in mice with diet-induced nonalcoholic steatohepatitis by lowering TNFR1 and TLR4 expression and ligand availability. J Nutr Biochem 2017;41:34-41. [PMID: 28038359 DOI: 10.1016/j.jnutbio.2016.12.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
424 Noureddin M, Zhang A, Loomba R. Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opin Emerg Drugs 2016;21:343-57. [PMID: 27501374 DOI: 10.1080/14728214.2016.1220533] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
425 Yadav SK, Adhikary B, Chand S, Maity B, Bandyopadhyay SK, Chattopadhyay S. Molecular mechanism of indomethacin-induced gastropathy. Free Radic Biol Med. 2012;52:1175-1187. [PMID: 22265930 DOI: 10.1016/j.freeradbiomed.2011.12.023] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 6.0] [Reference Citation Analysis]
426 Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, Dietze O, Strasser M, Datz C, Weiss G. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. The American Journal of Clinical Nutrition 2008;87:1374-83. [DOI: 10.1093/ajcn/87.5.1374] [Cited by in Crossref: 117] [Cited by in F6Publishing: 118] [Article Influence: 8.4] [Reference Citation Analysis]
427 Wong VW, Wong GL, Yu J, Choi PC, Chan AW, Chan HY, Chu ES, Cheng AS, Chim AM, Chan FK. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am J Gastroenterol. 2010;105:132-138. [PMID: 19809411 DOI: 10.1038/ajg.2009.560] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
428 Hazlehurst JM, Tomlinson JW. Non-alcoholic fatty liver disease in common endocrine disorders. Eur J Endocrinol 2013;169:R27-37. [PMID: 23653455 DOI: 10.1530/EJE-13-0296] [Cited by in Crossref: 51] [Cited by in F6Publishing: 22] [Article Influence: 5.7] [Reference Citation Analysis]
429 Duman DG, Ozdemir F, Birben E, Keskin O, Ekşioğlu-demiralp E, Celikel C, Kalayci O, Kalayci C. Effects of Pentoxifylline on TNF-α Production by Peripheral Blood Mononuclear Cells in Patients with Nonalcoholic Steatohepatitis. Dig Dis Sci 2007;52:2520-4. [DOI: 10.1007/s10620-006-9723-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
430 Petta S, Amato MC, Di Marco V, Cammà C, Pizzolanti G, Barcellona MR, Cabibi D, Galluzzo A, Sinagra D, Giordano C. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35:238-247. [PMID: 22117531 DOI: 10.1111/j.1365-2036.2011.04929.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.9] [Reference Citation Analysis]
431 Yahagi N, Shimano H, Matsuzaka T, Sekiya M, Najima Y, Okazaki S, Okazaki H, Tamura Y, Iizuka Y, Inoue N. p53 involvement in the pathogenesis of fatty liver disease. J Biol Chem. 2004;279:20571-20575. [PMID: 14985341 DOI: 10.1074/jbc.m400884200] [Cited by in Crossref: 81] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
432 Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, Uno M, Akahori H, Misu H, Sakurai M, Zen Y. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology. 2007;132:282-293. [PMID: 17241878 DOI: 10.1053/j.gastro.2006.10.014] [Cited by in Crossref: 161] [Cited by in F6Publishing: 164] [Article Influence: 10.1] [Reference Citation Analysis]
433 Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038-1048. [PMID: 26823198 DOI: 10.1016/j.metabol.2015.12.012] [Cited by in Crossref: 901] [Cited by in F6Publishing: 867] [Article Influence: 150.2] [Reference Citation Analysis]
434 Naik A, Košir R, Rozman D. Genomic aspects of NAFLD pathogenesis. Genomics. 2013;102:84-95. [PMID: 23545492 DOI: 10.1016/j.ygeno.2013.03.007] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 6.0] [Reference Citation Analysis]
435 Miller MH, Ferguson MAJ, Dillon JF. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease: Performance of non-invasive biomarkers in non-alcoholic fatty liver disease. Liver International 2011;31:461-73. [DOI: 10.1111/j.1478-3231.2011.02451.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
436 Eiszrich Á, Fehér J. Fatty Liver in Childhood. Hungarian Medical Journal 2008;2:519-31. [DOI: 10.1556/hmj.2.2008.28270] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
437 Mallick P, Shah P, Gandhi A, Ghose R. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice. Life Sci 2015;139:132-8. [PMID: 26334566 DOI: 10.1016/j.lfs.2015.08.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
438 Lee SJ, Yu WK, Park HR, Kim H, Kim JH, Park J, Shin KS. Improved effect of palatinose syrup bioconverted from sucrose on hyperglycemia and regulation of hepatic lipogenesis in male C57BL/6J mice. J Food Biochem 2020;44:e13201. [PMID: 32391610 DOI: 10.1111/jfbc.13201] [Reference Citation Analysis]
439 Li M, Reynolds CM, Segovia SA, Gray C, Vickers MH. Developmental Programming of Nonalcoholic Fatty Liver Disease: The Effect of Early Life Nutrition on Susceptibility and Disease Severity in Later Life. Biomed Res Int 2015;2015:437107. [PMID: 26090409 DOI: 10.1155/2015/437107] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
440 Miquilena Colina ME, García Monzón C. [Obesity and liver disease]. Gastroenterol Hepatol 2010;33:591-604. [PMID: 20206411 DOI: 10.1016/j.gastrohep.2009.12.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]